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A dysregulated Androgen Receptor (AR) transcriptional network is one of the main 
drivers behind prostate cancer initiation and development. Indeed, AR has always been a 
key target in prostate cancer therapeutics. A thorough understanding of the AR 
transcriptional network would shed valuable insights to prostate cancer etiology and 
contribute immensely to the development of new prostate cancer therapies. To function, 
AR has to interact and collaborate with a plethora of other transcription factors. It is the 
interplay between AR and its co-factors that ultimately define the output of the AR-
centric transcriptional program. Consequently, aberrant expression of AR co-factors 
would contribute to a deregulated androgen receptor transcriptional circuitry that favors 
prostate cancer progression.  
Prostate cancer was shown frequently to harbor recurrent gene fusions that led to over-
expression of the transcription factor, ERG.  The potential transcription crosstalk between 
AR and ERG is of exceptional interest as it represents a prostate cancer-specific 
collaboration that is suitable for therapeutic intervention. Herein, we sought to gain a 
deeper understanding on the AR and ERG transcriptional network in prostate cancer 
cells. By generating and analyzing a time-course Chromatin Immunoprecipitation-
Sequencing (ChIP-Seq) of AR and ERG, we provided valuable insights into the temporal 
and spatial aspects of genome-wide AR/ERG cistromic profiles. Coupled with siRNA 
knockdown experiments, we showed that ERG could function as a transcriptional co-
repressor of AR.  
viii 
 
Apart from ERG, several transcriptional co-repressors such as histone deacetylases 
(HDACs) and the polycomb repressor, EZH2, which are implicated for cancer 
progression, are also commonly over-expressed in prostate cancers. Interestingly, several 
studies have reported a correlation between the expression of HDACs, EZH2 and ERG in 
prostate cancers. To reveal insights into the possible interplay between AR, ERG and 
these co-repressors, we proceed on to generate extensive cistromic profiles of these 
factors prior and after androgen stimulation. We observed that these co-repressors, like 
ERG, were also recruited to AR enhancers upon androgen treatment. In addition, we 
found that while substantial overlaps are present between the genome-wide occupancy 
profiles of ERG, each distinct HDAC members and EZH2, they are not indistinguishable. 
This implies a distinct role for each respective co-repressor.  
Importantly, we assigned a functional role for the co-repressors in facilitating metastasis. 
Our results showed that ERG, HDACs and EZH2 transcriptionally suppressed the 
induction level of androgen induced cytoskeletal proteins that inhibit metastasis and 
maintain the epithelial phenotype in prostate cancer cells. Implicitly, VCL was validated 
as one such cytoskeleton protein.  
Taken together, our data suggested that, through their repressive effects, ERG, HDACs 
and EZH2 could co-operate in this AR centric transcriptional network to attain optimal 
androgen signaling for cancer progression. This finding highlighted a formerly 
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CHAPTER 1: INTRODUCTION 
1.1 Prostate Cancer Basics 
 
Prostate cancer is one of the most frequent cancers among the male population. 
According to current available statistics (Howlader et al., 2011). 1 in 6 American males 
are expected to be diagnosed with prostate cancer within their lifetime. Apart from 
hereditary factors, certain dietary and environmental factors were also shown to be 
correlated with prostate cancer incidence (Carter et al., 1990). Given the high prevalence 
of prostate cancers, intense research efforts have been and are still being invested to 
understand and to combat the disease.  
These efforts have resulted in significant progress for prostate cancer treatment. The 
seminal discovery by Charles Huggin that demonstrate the necessity of androgens (Male 
steroid hormones) in prostate cancer progression has led to the development of Androgen 
Deprivation Therapy (ADT) (Huggins, 1967; Huggins and Hodges, 2002). Clinically, 
most hormone naïve prostate cancers were shown to regress in response to ADT. 
However, recurrence is common with the disease progressing into aggressive, metastatic 
and castrate-resistant form through a variety of mechanisms (Feldman and Feldman, 






1.2 Androgens in Prostate Cells 
 
Past research has provided strong evidence that demonstrate the role of androgens in 
fueling prostate cancer growth and development (Huggins, 1967; Huggins and Hodges, 
2002). Physiologically, androgens are responsible for promoting male characteristics, 
which include but not limited to, regulating prostate gland development, maintenance and 
function (Cunha et al., 1987; Mooradian et al., 1987). There exist several types of 
androgens. The principal androgen in males is testosterone (T), which is usually 
metabolized and converted into its more potent counterpart, 5α-dihydrotestoterone (DHT) 
by the enzyme 5α-reductase (Russell and Wilson, 1994). Androgens as the cognate 
ligands of AR, typically exert their influence on cell biology through activating AR 
signaling. 
 
1.3 A Brief Description of AR 
 
AR is a member of the nuclear hormone receptor superfamily. Structurally, AR is 
comprised of several distinct functional domains, namely, a N-terminal domain (NTD) 
containing 2 transcriptional activation units (AF-1 and AF-5), a DNA binding domain 
(DBD) where 2 four-cysteine zinc-binding domains are located, a ligand binding domain 
(LBD) harboring another transcriptional activation unit AF-2 and a hinge region 
connecting LBD and DBD (Fig. 1.1) (Brinkmann et al., 1989; Chang et al., 1988; Jenster 
et al., 1995; Koochekpour, 2010). The functional domains of AR are consistent with the 
characteristics of a ligand dependent transcription factor. Being the predominant receptor 
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for androgens, AR is the main mediator for the genomic actions of androgens. The 
general simplified pathway for AR activation through androgen stimulation is as follows: 
After activation by androgens binding to its LBD, AR dissociates from prebound 
heatshock proteins (HSP), translocates into the nucleus and dimerizes. Within the 
nucleus, AR is recruited to the DNA via its DBD which structurally recognize the 
consensus DNA sequence AGAACANNNTGTTCT, the canonical motif for Androgen 
Response Elements (AREs) to mediate transcriptional regulation of the targeted gene 













 Figure 1.1 An Illustration on the Different Functional Domains of AR 
(Koochekpour, 2010). Structurally, AR comprise of a N-terminal domain, a DNA 




Figure 1.2 A Simplified Schematic on Androgen Signaling through AR (Saraon et 
al., 2011). AR is activated by its ligand, DHT, gets translocated into the nucleus and 
recruited to the chromatin to mediate transcription.  
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1.4 AR in Prostate Cancers 
 
The AR signaling pathway is known to be critical in prostate cancer biology. Studies 
have revealed that the AR transcriptional program is responsible for regulating genes that 
are responsible for driving proliferation, survival and differentiation in prostate cancer 
cells (Buchanan et al., 2001; Debes and Tindall, 2002; Heinlein and Chang, 2004; 
Schiewer et al., 2012; Shen and Abate-Shen, 2010). Being the signaling core of this 
transcriptional program, the transcription activity of AR is crucial to the final output of 
the pathway and hence prostate cancer progression (Buchanan et al., 2001; Debes and 
Tindall, 2002; Heinlein and Chang, 2004; Schiewer et al., 2012; Shen and Abate-Shen, 
2010). To take advantage of this relationship, a panel of AR direct transcriptional targets, 
including PSA, has been utilized as the main biomarkers for monitoring prostate cancer 
progression (Makarov et al., 2009). Furthermore, modulation of AR, the chief therapeutic 
target in prostate cancer treatment, has shown to be effective in the treatment of hormone 
naïve prostate cancers (Crawford et al., 1989). Although most prostate cancers eventually 
turn androgen independent (Feldman and Feldman, 2001), these advanced malignancies 
were shown to be still reliant on the AR signaling pathway for maintenance and continual 
progression (Chen et al., 2004; Zhang et al., 2003). Since castrate-resistant prostate 
cancers, while exhibiting resistant to anti-androgens, are still dependent on AR for 
survival, enhanced therapeutic targeting of AR in these forms of cancer should still be 
effective. This led to the development of second generation anti-androgens which have a 
higher affinity to AR in comparison to the currently used anti-androgens (Tran et al., 
2009). Within expectations, these compounds have exhibited great potential in the 
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treatment of “androgen independent” prostate cancers (Tran et al., 2009). Second-site AR 
antagonists that target AR allosterically were also demonstrated to block AR action and 
block proliferation in castrate-resistant prostate cancer cells (Joseph et al., 2009). These 
further lend support to the feasibility of targeting AR as a therapeutic option in androgen 
independent cancers. Hence, it is imperative that we elucidate and understand the 
mechanisms underlying the transcriptional actions of AR so as to develop better 
therapeutic targeting strategies for treating castrate-resistant prostate cancers.    
 
1.5 The Transcriptional Complex of AR 
 
As a transcription factor, AR does not function alone. Gene transcription regulation via 
AR is a well-regulated process involving the participation of a diversity of other 
transcriptional factors. The functionality of AR-mediated transcription depends on a 
series of coordinated events which involve chromatin remodeling, epigenetic 
modifications, chromosomal looping and polymerase tracking (Wang et al., 2005). To 
gain understanding on the AR transcriptional machinery and its workings, previous 
efforts were focused on an individual gene level. The AR activated target gene, PSA, is 
one of the candidates most extensively studied model (Cleutjens et al., 1996; Shang et al., 
2002; Wang et al., 2005) for insights into AR-mediated transcription. Transcriptional 
regulation of the PSA gene is governed by the co-operative actions of its AR bound 
proximal promoter and a distal enhancer (Shang et al., 2002; Wang et al., 2005). The 
proximal promoter of the PSA gene harbors 2 AREs (Cleutjens et al., 1996) while its 
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enhancer (4.2kb upstream of TSS) harbors 1 ARE (Cleutjens et al., 1997). Apart from 
AR, other co-operative transcription factors including  histone acetylases (HATs), histone 
demethylases, mediator complexes, and polymerases are also recruited to the PSA 
enhancer and promoter (Louie et al., 2003; Metzger et al., 2005; Shang et al., 2002; 
Wang et al., 2005; Wang et al., 2002; Yamane et al., 2006), resulting in the formation of 
an AR transcriptional activator complex (Fig. 1.3). This AR transcriptional complex is 
responsible for initiating the required chromatin remodeling and epigenetic modifications 
that ensure chromatin competency for transcriptional regulation. A multitude of AR 
transcriptional collaborators are known to be recruited via the AF-1 and AF-2 domains of 
AR. For instance, co-activators such as P160 are recruited to the chromatin via 
association with the intra-molecular interaction between AF-1 and AF-2 of AR (Alen et 
al., 1999; He et al., 1999). Upon their engagement with the AR, some of these 
collaborators in turn mediate the assembly of other transcription factors, ultimately 
forming the AR transcriptional complex. The TRAP220/Med1 co-activator upon 
recruitment to AR serves to append the whole mediator complex to the chromatin for the 
direct recruitment of other general transcription factors (GTFs) and pol II (Lewis and 
Reinberg, 2003; Wang et al., 2005; Wang et al., 2002). Co-operation between the PSA 
enhancer and promoter is achieved through chromatin looping and sharing a core AR 
transcriptional complex (Shang et al., 2002; Wang et al., 2005). RNA polymerase II 
which is strongly recruited to the PSA enhancer then tracks to the promoter to enhance 
PSA gene transcription (Wang et al., 2005). Although much is already shown about the 
AR activator transcriptional complex regulating PSA transcription, the exact nature and 
dynamics of the complex is still unclear. Furthermore, apart from PSA, the AR 
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transcriptional regulatory machineries of hundreds of other AR target genes remain 















Figure 1.3  A Model of the AR Transcriptional Complex at the Enhancer and 
Promoter of PSA after Androgen Stimulation (Shang et al., 2002). Upon DHT 
stimulation, AR gets recruited to the cis-regulatory elements and initiates the recruitment 
of transcriptional cofactors such as p300 and p160. Finally, RNA polymerase II is also 














1.6 Techniques for Genome-Wide Analysis of AR Binding Sites (ARBS) 
in Prostate Cancer Cells 
 
The development of molecular biology has brought about unprecedented insights into 
cellular biology. Experimental research utilizing molecular biology techniques has 
elucidated much detail on the workings of cellular processes such as cell metabolism, cell 
signaling, transcription, translation, protein degradation and transportation. As discussed 
earlier, much progress has also been made on the field of AR transcriptional regulation. 
However, past studies were largely based on a single or a few genes (Cleutjens et al., 
1997; Cleutjens et al., 1996; Shang et al., 2002; Wang et al., 2005) that provided limited 
information on the attributes of AR-mediated transcription at large. From gene profiling 
studies, it is known that hundreds of genes are actually regulated by androgen/AR 
(Holzbeierlein et al., 2004; Kazmin et al., 2006; Tan et al., 2012) in prostate cancer cells. 
In addition, time course gene expression profiling of androgen regulated genes revealed 
high differential expression kinetics among these genes (Tan et al., 2012). This suggests 
that the androgen regulated genes are likely to be regulated by a set of AR bound cis-
regulatory sites that could possibly alter with the duration of androgen signaling. 
However, until recently, unlike AR induced gene expression profiles, AR cis-regulatory 
elements were comparatively understudied and there was no analysis of AR occupied cis-
regulatory elements on a large scale. A large reason for this was the lack of a high 
throughput technology to identify ARBS in prostate cancer cells.  Recently, the advent of 
experimental techniques such as Chromatin Immunoprecipitation coupled with 
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microarray (ChIP-chip) and Chromatin Immunoprecipitation coupled with massively 
parallel DNA sequencing (ChIP-seq) has provided the impetus for such studies. 
 
1.6.1 ChIP-chip VS ChIP-seq 
 
ChIP-chip and ChIP-seq are both high throughput methods for identifying and 
interrogating protein-DNA interactions in-vivo. They are both high throughput extensions 
of the Chromatin Immunoprecipitation (ChIP) technique. For both techniques, ChIP is 
first performed via crosslinking the interaction between the protein and DNA. Sonication 
is then performed to shear the chromatin into short pieces (~500bp). Immunoprecipitation 
to pull down the desired protein bound DNA fragment is then performed using specific 
antibodies against the protein of interest.  For ChIP-chip, the pulled down DNA is then 
amplified and then hybridized on a tiling array for detection (Fig. 1.4), while ChIP-Seq 
involved the sequencing of the pulled down DNA and subsequent mapping back to the 
reference genome (Fig. 1.5).  
The ChIP-chip technique was first utilized to establish ARBS in-vivo (Bolton et al., 2007; 
Massie et al., 2007; Wang et al., 2007).  Although these studies have shed light on the 
rough landscape of the AR transcriptional regulatory network in prostate cancer cells, the 
shortfalls of the ChIP-chip technology is apparent. For instance, the resolution of the 
identified binding sites in ChIP-chip technology is low (i.e. few kb). Apart from that, the 
ChIP-chip technique is unable to interrogate repetitive regions of the genome and 
requires quite a huge amount of starting DNA material. Furthermore, ChIP-chip 
experiments are only possible depending on the availability of tiling arrays (which can be 
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costly if customization is required). In contrast, the ChIP-Seq emerged as an attractive 
alternative and offers several advantages over the ChIP-chip technology (Park, 2009) 
(Table 1). Consequently, recent studies have adopted ChIP-Seq as the preferred method 
for studying genome-wide ARBS (Tan et al., 2012; Wang et al., 2011; Yu et al., 2010b). 
Nevertheless, these 2 techniques have successfully advanced this research field, enabling 
a more detailed characterization of the AR cistrome (A genome-wide map of AR 













Figure 1.4  The Experimental Flow of ChIP-chip Technology (Pugh and Gilmour, 
2001) 
 





















1.6.2 The prospect of Next generation Sequencing (NGS) Technologies in 
Prostate Cancer Genomic Research 
 
The advent of the NGS and its potential applications is likely to revolutionize genomic 
studies. NGS technology has endowed researchers the capability to examine in 
unprecedented details, the genomic profiles of different biological systems with 
unparalleled speed and ease. With its sheer technological power and potential, NGS 
technology has undoubtedly positioned itself as an indispensable driving force in future 
genomic research. In fact, most of the recent breakthroughs seen in the field are a result 
of NGS technology application. Correspondingly, future genomic studies on the AR 
transcriptional network in prostate cancers would likely hinge heavily on the further 
development of NGS technology. 
 
1.7 Analyzing the AR Cistrome in Prostate Cancer Cells 
 
Since AR functions primarily as a transcription factor in response to androgens, the 
genomic locations and characteristics of ARBS will directly affect the role of AR in 
regulating transcription. An understanding of the genomic features and distribution 
patterns of the AR cistrome in prostate cancer cells will contribute to the comprehension 
of the AR transcriptional regulatory mechanisms and the identities of the target genes it 
regulate. For instance, direct target genes of AR could be possibly identified from the 




1.7.1 Location Analysis of ARBS in Prostate Cancer Cells 
 
Initially, as with other transcription factors such as the promoter-bound E2F transcription 
factor family (Xu et al., 2007), it was generally assumed that genome-wide AR chromatin 
occupancy studies would allow easy identification of primary AR target genes 
responsible for the diverse downstream cascades of androgen signaling. However, AR 
was found generally to regulate transcription through occupying distal enhancers far 
away from the transcriptional start sites of regulated genes (Tan et al., 2012; Wang et al., 
2007; Yu et al., 2010b). Consequently, this poses a major challenge in the determination 
of targets genes that are directly regulated by specific AR cis-regulatory elements. 
Moreover, in comparison to several hundreds of androgen regulated genes, thousands of 
ARBS were detected across the genome (Tan et al., 2012; Wang et al., 2009b; Yu et al., 
2010b). This further adds to the complexity of the problem in associating binding sites 
with regulated genes whereby a single gene could be regulated by multiple enhancers 
(through extensive chromatin loopings). There is also the possibility of the presence of 
large numbers of AR enhancers that are non-functional under this situation which may 
only be transcriptionally activated under specific signaling conditions. Interestingly, the 
recruitment to distal enhancers might be a recurring feature for nuclear hormone receptor 
mediated transcriptional regulation (Carroll et al., 2006; Lefterova et al., 2008). 
 
1.7.2 The Androgen Response Elements and other Motifs in ARBS 
 
Like other DNA binding transcription factors, the AR DNA binding domain is mainly 
responsible for determining its DNA binding specificity and affinity. To determine the 
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DNA motifs to which AR binds (termed the Androgen Response Elements (AREs), 
earlier studies had performed DNAse footprinting and electrophoretic mobility shift 
assays (Cleutjens et al., 1997; De Vos et al., 1991) with cloned androgen-responsive 
enhancers near androgen regulated genes. Through these efforts, AR was found to bind to 
imperfect inverted repeats with a three base pair spacer bearing similarities to the 
sequence 5′-AGAACANNNTGTTCT-3′. However, this identification approach was 
tedious and low throughput in nature for the discovery of possible ARE sequences. 
Subsequently, a PCR-based SELEX (Systematic Evolution of Ligands by Exponential 
Enrichment) approach was utilized (Nelson et al., 1999; Roche et al., 1992; Zhou et al., 
1997) to meet this challenge. Not only do these studies confirm AR’s high binding 
affinity to sequences similar to 5′-AGAACANNNTGTTCT-3′, they also demonstrated 
that AR exhibit specific binding preferences to direct repeats and to certain nucleotides at 
the flanking or spacer region of AREs that differ from other Class I steroid nuclear 
hormone receptors (GR, PR and MR) (Nelson et al., 1999; Zhou et al., 1997). Even 
though these studies have extended our understanding on the binding specificity of AR, 
they only provided information on the in-vitro binding characteristics of AR. The in-vivo 
features of ARBS are likely to be influenced by the presence of other collaborative 
transcription factors and the chromatin status of the binding region. Unsurprisingly, by 
utilizing Chromatin Immunopreciptiation (ChIP) assays to interrogate AR occupancy in-
vivo, a significant proportion of perfect AREs present in the genome were found to be 
devoid of AR binding in the LNCaP prostate cancer cells (Horie-Inoue et al., 2006). 
Nevertheless, this result confirms the disparity between in-vitro and in-vivo binding 
features of AR. Since ChIP assays could be used to identify in-vivo ARBS, the 
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application of a high throughput ChIP-based approach would enable the determination of 
the AR cistrome. To this end, methodologies such as ChIP on chip (ChIP-chip) (Iyer et 
al., 2001), ChIP paired-end tags (Wei et al., 2006) (ChIP-PET) and ChIP sequencing 
(Johnson et al., 2007) (ChIP-Seq) were developed. The application of these high 
throughput AR ChIP assays in prostate cancer cells has provided a large number of novel 
bona-fide ARBS for analysis. Although the canonical ARE consensus motif was 
observed to be enriched in the ARBS identified by several different studies (Bolton et al., 
2007; Massie et al., 2007; Wang et al., 2007; Yu et al., 2010b), a substantial portion of 
the ARBS were reported to be devoid of canonical AREs. Through a chromosome wide 
AR ChIP-chip experiment in LNCaP cells (Wang et al., 2007), it was reported that only 
10% of the 90 ARBS found on chromosome 21 and 22 harbor the canonical AR 
consensus motif. Interestingly, 68% of the 90 ARBS were described to contain non-
canonical AREs. These non-canonical AREs are either in the form of isolated half AREs 
or half AREs arranged in a head-to-head, tail-to-tail or direct repeat manner with a 
varying spacer length between zero to eight nucleotides. Similarly, the other study 
(Massie et al., 2007) that performed AR ChIP on chip using promoter tiling arrays 
reported a relative small proportion of ARBS (~26.8%) harboring canonical AREs with 
the majority of the ARBS (~57.2%) having only half ARE motifs. In contrast, canonical 
form of AREs were found in majority of ARBS (~69%) identified in HPr-1AR cells 
through AR ChIP on chip assay that utilize customized tiling arrays interrogating ~104kb 
genomic regions centered on the transcription start sites of 548 candidate hormone 
responsive genes (Bolton et al., 2007). Analysis of our AR ChIP-Seq data in LNCaP cells 
(Tan et al., 2012) revealed canonical AREs in 44% and half AREs in 19% of the ARBS. 
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However, we were not able to detect enrichment of other previously reported forms (apart 
from ARE direct repeats of three base pair spacer) of non-canonical AREs (Wang et al., 
2007). Indeed, a recent paper provided data that cast doubts on the functionality of the 
non-canonical AREs (Denayer et al., 2010). Despite substantial differences between these 
high throughput ChIP-based studies, these results largely confirmed that in-vivo, AR is 
not recruited exclusively to rigid canonical ARE motifs determined in-vitro. The 
surprisingly low occurrence of AREs in ARBS has provided the impetus for investigating 
the presence of other enriched motifs that could aid AR recruitment indirectly. Indeed, 
through motif enrichment analysis, motifs of several transcription factors were found to 
be overrepresented in ARBS and subsequently validated as transcriptional collaborators 
of AR in several studies (Massie et al., 2007; Tan et al., 2012; Wang et al., 2007; Yu et 
al., 2010b). 
 
1.7.3 AR Cistrome in Advanced Prostate Cancers 
 
As mentioned earlier, studies have demonstrated that AR activation remains critical to the 
survival and growth of castrate-resistant prostate cancers (Hara et al., 2003; Zhang et al., 
2003). However, the exact role of AR in advanced prostate cancers is still largely 
unknown. Recent advances in AR cistromic studies have provided insights on the 
alterations to the AR transcriptional program accompanying prostate cancer progression. 
For instance, Wang and his colleagues provided evidence for a distinct AR transcriptional 
program in androgen independent prostate cancers (Wang et al., 2009b). Specifically, 
they found that relative to hormone dependent prostate cancers, AR display distinct 
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chromatin occupancy preferences to the cis-regulatory elements of a substantial number 
of cell cycle and M-phase genes in castrate-resistant prostate cancers. An example is the 
Ubiquitin-conjugating enzyme E 2C (UBE2C). Consequently, AR exclusively regulates 
the expression of these genes to promote proliferation in androgen independent prostate 
cancer cells but not in its androgen dependent counterpart. Remarkably, this study has 
provided novel insights to the AR transcriptional network in prostate cancers by 
demonstrating the capability of AR in mediating different transcriptional programs with 
prostate cancer progression. A more recent study has identified a possible mechanism 
that could regulate the transcription plasticity of AR (Wang et al., 2011).  
 
1.8 Transcriptional Collaborators of AR 
 
Transcription co-factors are able to exert profound influence on the AR transcriptional 
output through the regulation of AR’s transcription activity. In prostate cancers, 
transcriptional co-regulatory factors of AR are commonly expressed aberrantly. 
Consequently, the AR transcriptional network is altered to one that promotes 
oncogenesis. Indeed, studies have suggested that altered expression of AR co-activators 
could contribute to castrate-resistant prostate cancers (Devlin and Mudryj, 2009). In 
another testament to the importance of these transcription collaborators, a recent study 
had identified the presence of mutated AR co-factors that could deregulate AR signaling 
in prostate cancers (Taylor et al., 2010). Given mounting evidence that point to the 
emergence of a transformed AR transcriptional circuitry essential for prostate cancer 
progression, it would be of therapeutic interest to identify and understand the other 
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different AR transcription collaborators that could possibly contribute towards the 
reshaping of AR cistrome and its transcriptional program. Next, I will give a discussion 
on two major AR transcriptional collaborating factors in prostate cancer cells. 
 
1.8.1 Forkhead Box Protein A1  
 
Recent studies have demonstrated the presence of transcription factors already preloaded 
to potential AR-enhancers prior androgen stimulation and AR recruitment (Sahu et al., 
2011; Wang et al., 2011; Wang et al., 2007). This particular class of transcription factors 
was termed as pioneering factors. Their presence at these cis-regulatory elements was 
usually shown to be necessary for subsequent recruitment of AR or other transcriptional 
co-factors (Sahu et al., 2011; Wang et al., 2011; Wang et al., 2007). Correspondingly, 
pioneering factors were generally implicated to facilitate and prime the recruitment of 
other transcription factors through chromatin remodeling. Although the exact 
mechanisms responsible for initiating chromatin remodeling is likely to be specific for 
the different pioneering factors and is still largely unclear, a variety of general 
mechanisms have been studied and put forward (Magnani et al., 2011). Pioneering factors 
were suggested to be able to modulate the nucleosomal structure and facilitate 
transcription factor recruitment by directly evicting the nucleosomes, modulating higher-
order chromatin structure and initiating/maintaining epigenetic modifications that are 
associated with potential transcription factor binding sites (Magnani et al., 2011). 
Forkhead box protein A1 (FoxA1) is one of the identified pioneering factors for AR-
mediated transcription (Sahu et al., 2011; Wang et al., 2011). The role of FoxA1 as a 
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pioneering factor was first discovered in the estrogen receptor (ER) transcriptional 
network system in breast cancers (Carroll et al., 2005). Apart from ER, FoxA1 was also 
shown to function as a pioneering factor of AR in prostate cancers (Lupien et al., 2008). 
In concordance with its purported role as a major pioneering factor of both estrogen 
receptor (ER) and AR, the cistromes of FoxA1 were revealed to overlap significantly 
with that of ER, in breast cancers and AR, in prostate cancers (Lupien et al., 2008). 
Intriguingly, even though FoxA1 binding was largely independent to estrogen or 
androgen stimulation, the cistrome of FoxA1 identified in breast and prostate cancers was 
significantly different (Lupien et al., 2008). The large number of lineage-specific FoxA1 
binding sites found was functionally responsible for the determination of tissue-specific 
transcription programs of the nuclear receptors in breast and prostate cancers through 
pioneering differential tissue-specific AR and ER cistromic profiles (Lupien et al., 2008). 
The mechanisms underlying FoxA1 specific recruitment to the chromatin were also 
investigated. FoxA1 binding sites were found to be enriched for H3K4me1 and 
H3K4me2 histone marks (Lupien et al., 2008; Sahu et al., 2011; Serandour et al., 2011). 
Importantly, the removal of these marks through LSD1 overexpression was shown to 
abrogate FoxA1 binding (Lupien et al., 2008). In contrast, silencing of FoxA1 did not 
affect the H3K4 methylation levels but reduced DNAse I sensitivity at FoxA1 binding 
sites (Lupien et al., 2008). This data supports a model in which FoxA1 is recruited to 
H3k4me1/me2 sites to initiate chromatin opening and remodeling, priming the region for 
subsequent AR/ER recruitment. 
Given the general consensus on FoxA1’s role as a critical pioneering factor for AR, it 
would be important to determine its regulation of the AR transcriptional network in 
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prostate cancer cells. To address this, two recent studies (Sahu et al., 2011; Wang et al., 
2011) separately performed in-depth analysis of the AR cistromes before and after FoxA1 
depletion in prostate cancer cells. Even though the experimental conditions between the 
two studies were somewhat different, similar observations were derived (Sahu et al., 
2011; Wang et al., 2011). The analyses defined three classes of ARBS that were 
differentially affected by FOXA1 depletion: The gained ARBS, the lost ARBS and the 
unchanged ARBS. Through coupling the AR cistromic maps with microarray profiling 
experiments, it was revealed that the genes regulated by the three different classes of 
ARBS had unique biological functions (Sahu et al., 2011; Wang et al., 2011), providing a 
mechanism in which FoxA1 determines prostate cancer progression. Intriguingly, even 
though the two studies both demonstrated similar capabilities of FoxA1 in 
reprogramming the AR transcriptional network, the two studies claimed contrasting 
phenotypical and functional effects exerted by FoxA1 in prostate cancer progression. In 
the first study (Wang et al., 2011), decreased levels of FoxA1 were associated with 
castrate resistant, poor prognostic prostate tumours. Moreover, depletion of FoxA1 
enhanced S-phase cell entry of LNCaP prostate cancers under reduced androgen 
conditions. On the contrary, the second study (Sahu et al., 2011) associate low FoxA1 
levels with good patient prognosis. While these opposing results may seem contradicting, 
they might be pointing to a dual role of FoxA1 on cancer progression under different 
subtypes or stages of prostate cancer. However, further experimentations would definitely 




1.8.2 The ETS Transcription Factor: ERG 
 
The ETS family encompass a class of transcription factors that have a highly conserved 
DNA binding domain termed the ETS domain (Karim et al., 1990). The ETS domain is a 
winged helix-turn-helix structure that binds to DNA with the purine-rich core sequence 
GGAA (Karim et al., 1990; Kodandapani et al., 1996; Liang et al., 1994).  The ETS 
transcription factors were known to play important roles in regulating a wide diversity of 
cellular and developmental processes including cell proliferation, cell differentiation, 
cellular senescence, haematopoiesis, angiogenesis and apoptosis (Ohtani et al., 2001; 
Sevilla et al., 1999; Sharrocks, 2001; Taylor et al., 1997; Treisman, 1994).  Since all of 
the ETS family members recognized the same core DNA sequence as a result of their 
highly conserved ETS domain, the action specificity of each ETS transcription factor are 
generally specified by interacting with specific co-regulatory protein partners  and/or by 
post translation modifications such as phosphorylation and ubiquitination during 
activation of cellular signaling (Chakrabarti et al., 2000; Li et al., 2000; Sharrocks, 2001; 
Wasylyk et al., 1998). The function of ETS transcription factors as activators or 
repressors was also dependent on cellular context, regulated by their protein interaction 
partners and linked to activation of specific signal transduction pathways (Sharrocks, 
2001; Sharrocks et al., 1997). Interestingly, several ETS transcription factors were found 
to be highly associated with cancers through gene fusion with another protein. Examples 
include the EWS-ERG, EWS-FLI1 gene fusion in Ewing’s sarcoma (Giovannini et al., 
1994) and the TEL-JAK2 in leukemia (Lacronique et al., 1997; Peeters et al., 1997).  
Of high relevance to prostate cancers, a recent landmark paper reported the discovery of 
recurrent ETS fusion genes (Tomlins et al., 2005). Strikingly, it was reported that almost 
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50% of prostate cancers from PSA screened cohorts (Kumar-Sinha et al., 2008) actually 
harbor recurrent ETS gene fusions. Out of all the different types of ETS gene fusion, the 
most commonly occurring variant is the TMPRSS2-ERG fusion gene (Kumar-Sinha et 
al., 2008). This fusion involves the promoter of the androgen regulated gene, TMPRSS2 
to fuse to the promoter of ERG gene, rendering the expressing of ERG androgen 
dependent (Fig. 1.6). Other than ERG, ETS family members such as ETV1, ETV4 and 
ETV5 are also found to be involved in gene fusions in prostate cancers albeit at a 
substantially lower frequency (Kumar-Sinha et al., 2008). Given the widespread 
prevalence of ERG gene fusion in prostate cancers, intense research efforts have been 
directed at elucidating its function in prostate cancer progression. Consequently, ERG 
was established as a key player in prostate oncogenesis in multiple studies (Carver et al., 
2009; King et al., 2009; Tomlins et al., 2008; Zong et al., 2009). Specifically, ERG was 
shown to synergize to PTEN loss and PI3K pathway activation to promote prostate 
cancer progression to invasive adenocarcinoma (Carver et al., 2009; King et al., 2009). In 
addition, increased ERG expression in the prostate cells was linked to the activation of 
the plasminogen activation and the matrix metalloproteinase (MMP) pathways through 
direct transcriptional upregulation of pathway components (Fig. 1.6) (Tomlins et al., 
2008). Interestingly, ERG was also shown to co-operate with AR to induce the formation 
of poorly differentiated and invasive prostate carcinomas in mice (Zong et al., 2009). 
This posits a potential AR and ERG crosstalk that might be crucial for prostate cancer 
development and progression. Given that both AR and ERG are transcriptional factors, it 
is tempting to speculate a transcriptional collaboration (Fig. 1.6).  
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Indeed, the ETS binding motif was first found to be over-enriched at AR-bound promoter 
regions identified in an AR ChIP-on-chip study on prostate cancer cells (Massie et al., 
2007). Through further ETS-1 ChIP experiments, the same study went on to show 
androgen-induced recruitment of ETS-1 to several AR-bound promoters (Massie et al., 
2007). This was the first study to demonstrate the potential of ETS members as 
collaborative factors of AR in regulating transcription. Subsequently, both ETV1 (Shin et 
al., 2009) and ERG (Sun et al., 2008) were also revealed to regulate AR signaling 
through functioning as AR transcriptional co-factors. Intriguingly, while ETS-1 and 
ETV1 were implicated as transcriptional activators of AR (Feed Forward Regulation) 
(Massie et al., 2007; Shin et al., 2009), ERG was recently shown by others to exert 
repressive (Feedback Regulation) influence on AR dependent transcription (Sun et al., 
2008; Yu et al., 2010b). As this finding suggests a different role for each unique ETS 
gene fusion in prostate oncogenesis, this finding implies a need to further stratify ETS 
fusion positive prostate cancers into more specific subgroups for diagnosis and treatment. 
To understand the transcriptional network of AR and ERG, Yu and colleagues (Yu et al., 
2010b) have generated genome-wide cistromic profiles of AR and ERG in ERG fusion 
positive VCaP prostate cancer cells. They observed substantial overlap between the 
cistromes of AR and ERG and hence provide evidence for a genome-wide transcriptional 
collaboration between the two factors. ERG was shown to occupy the AR enhancers as 
well as the promoter of AR target genes. Importantly, ERG was found to suppress 
androgen induced differentiation markers and consequently implicated as a suppressor of 
AR-mediated epithelial differentiation (Yu et al., 2010b). Although this study (Yu et al., 
2010b) has provided substantial insights on the transcriptional collaboration between AR 
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and ERG, several important questions on the cross-talk remains unanswered. Some of 
these unresolved questions were highlighted by Chen and Sawyers (Chen and Sawyers, 
2010). For instance, the model AR target genes that were shown to be repressed by ERG 
(Yu et al., 2010b) were only epithelial differentiation markers with no known functional 
role in oncogenesis. Consequently, it is important to identify the ERG repressed AR 
target genes that are responsible for cancer progression. Also, the mechanics of this 
particular transcriptional collaboration under androgen signaling remains vague as the 
























1.9 Reduced Androgen Signaling in Advanced Metastatic Prostate 
Cancers 
 
A partial attenuation of androgen signaling was suggested to be a common feature of 
metastatic and advanced prostate cancers (Yu et al., 2010b). This was a surprising finding 
as AR is commonly known to enhance prostate cancer development and maintenance 
through driving proliferation and survival (Heinlein and Chang, 2004). In normal prostate 
development, apart from driving proliferation, AR is also known to promote 
differentiation of prostate cells (Kelly and Yin, 2008). Likewise, AR is implicated to 
drive a pro-differentiation transcription program in prostate cancer cells (Sun et al., 2008; 
Yu et al., 2010b). Consequently, this part of AR activity is inhibitory to the aggressive 
stem cell-like dedifferentiated state that is usually exhibited by metastatic prostate 
cancers (Yu et al., 2007b). To subvert this, in ERG-fusion positive prostate cancers, ERG 
functioned to directly mediate partial suppression of androgen signaling for prostate 
cancer advancement (Sun et al., 2008; Yu et al., 2010b). Apart from ERG, multiple 
transcriptional co-repressors implicated for cancer progression, are also commonly over-
expressed in prostate cancers. These co-repressors were generally thought to exert their 
oncogenic influence through constitutive repression of tumor suppressor genes. However, 
their role in androgen signaling is still relatively unclear. It would thus be interesting to 
investigate their function, if any, in the AR transcriptional network and determine if they 
act in a similar way as ERG. In this study, we decide to focus our investigation on the 
HDACs (specifically HDAC1, HDAC2 and HDAC3) and EZH2 co-repressors as a result 
of their known importance in prostate cancer development and their relationship with AR 
and ERG.    
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1.10 Histone Deacetylases in Prostate Cancers 
 
HDACs are a class of enzymes that catalyze the removal of acetyl groups from either 
transcription factors or the tails of histones to regulate the transcription of target genes 
(de Ruijter et al., 2003; Glozak and Seto, 2007). Deacetylation of the histones results in 
chromatin compaction, thereby restricting the recruitment of transcriptional machinery 
(RNA polymerases and other GTFs) (Fig. 1.7). Consequently, the transcriptional activity 
of the target gene is reduced or abolished (de Ruijter et al., 2003; Glozak and Seto, 2007). 
Apart from histones, deacetylation of transcription factors by HDACs could cause a 
change in protein conformation, which in turn alters the activity of the said transcription 
factor (Fig. 1.7) (Glozak and Seto, 2007). On the other hand, HATs act in counter to the 
activity of HDACs, catalyzing the acetylation of histones leading to the enhancement of 
transcriptional activity. Therefore, the regulation of net activity between HDACs and 
HATs could serve as a rheostat to the transcriptional output of the target genes (Fig. 1.7) 
(Glozak and Seto, 2007). 
Essentially, HDACs are categorized into different classes according to their sequence 
similarity, domain organization and homology to yeast counterparts (Table 2) (Abbas and 
Gupta, 2008; de Ruijter et al., 2003; Dokmanovic et al., 2007; Gregoretti et al., 2004). 
HDACs usually are involved in multi-subunit repressive complex recruited by specific 
transcriptional co-repressors. For instance, HDACs could be recruited by nuclear receptor 
co-repressors such as N-CoR and SMRT to form part of the repressor complex for gene 
suppression (Abbas and Gupta, 2008). 
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Out of all the HDACs, the class I members, HDAC1, HDAC2 and HDAC3, were shown 
to be frequently over-expressed and to promote metastasis in prostate cancers (Wang et 
al., 2009a; Weichert et al., 2008). Other than being suggested to be involved in DNA-
methylated repression of tumor suppressors that inhibit cellular proliferation and survival 
(Patra et al., 2001), HDACs are also known to impact AR-mediated transcription in 
prostate cancers (Abbas and Gupta, 2008; Gaughan et al., 2002; Gaughan et al., 2005; 
Shang et al., 2002). In fact, AR and HDAC1 were demonstrated to form a complex at the 
PSA promoter (Gaughan et al., 2002; Gaughan et al., 2005). AR was demonstrated to be 
directly de-acetylated by HDAC1, culminating into the downregulation of AR activity 
(Gaughan et al., 2002; Gaughan et al., 2005). A de-acetylated AR was shown to be de-
stabilized through Mdm2-mediated ubiquitylation (Gaughan et al., 2005). In another 
study, HDAC1 and HDAC2 were shown to be only recruited to the PSA promoter to 
form the corepressor complex after bicalutamide (androgen antagonist) stimulation 
(Shang et al., 2002). Given the importance of HDACs and AR in prostate cancers, it was 
suprising that, to date, we found no published study on the genome-wide cross-talk 
between HDACs and AR. 
It was interesting for us to note that high levels of HDAC1 coupled with a low HDAC1 
target gene profile expression are key features of TMPRSS2-ERG fusion positive 
prostate cancers (Gupta et al., 2010; Iljin et al., 2006). Furthermore, ERG fusion positive 
prostate cancer cells were shown to be particularly sensitive to HDAC inhibitor treatment 
(Bjorkman et al., 2008). Accordingly, ERG fusion positive prostate cancers were 
postulated to adopt epigenetic reprogramming through HDAC1 as an oncogenicity 
driving mechanism (Bjorkman et al., 2008). This particular feature of ERG positive 
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Table 2 Different Classes of HDACs (Abbas and Gupta, 2008) 
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1.11 The Methyltransferase Polycomb Protein EZH2 in Prostate 
Cancers 
 
The enhancer of zeste homolog 2 (EZH2), is a member of the polycomb group family 
that catalyzes the trimethylation of histone H3K27 at the promoter of genes for targeted 
transcriptional repression (Fig. 1.8) (Cao and Zhang, 2004). EZH2 was first discovered as 
part of a multiprotein polycomb complex that mediates the silencing of HOX genes for 
proper embryonic development in Drosophila (Fig. 1.8) (Franke et al., 1992). EZH2 was 
postulated to be an important regulator of development as its deletion in mice resulted in 
early lethality during early stage of development (O'Carroll et al., 2001). In embryonic 
stem cells, EZH2 usually functions in complex with Eed and Suz12, forming the 
polycomb repressor complex 2 (PRC2) to silence the expression of genes that are 
involved in differentiation and in the regulation of specific developmental lineages (Fig. 
1.8) (Boyer et al., 2006; Lee et al., 2006b). EZH2 was also shown to be involved in X-
chromosome inactivation (Fig. 1.8) (Plath et al., 2003). In cancers, the oncogenic role of 
EZH2 in cancer progression has been well established in a diversity of cancers including 
breast, prostate and lymphoma (Kleer et al., 2003; Neff et al., 2012; Simon and Lange, 
2008; Varambally et al., 2002). Aberrantly high expression of EZH2 was demonstrated to 
inhibit differentiation, drive proliferation, metastasis and angiogenesis in cancers (Bryant 
et al., 2007; Chang et al., 2011; Li et al., 2010; Lu et al., 2010; Min et al., 2010; Richter 
et al., 2009; Simon and Lange, 2008). Accordingly, elevated levels of EZH2 were 
commonly associated with advanced cancers exhibiting poor prognostic outcomes 
(Simon and Lange, 2008) (Yu et al., 2007b). In particular, EZH2 were found to be 
commonly overexpressed in invasive and castrate-resistant prostate cancers (Varambally 
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et al., 2002). The oncogenic capability of EZH2 has been strongly linked with its 
methyltransferase activity as the presence of a functional SET domain is vital for EZH2 
mediated repression of its target genes in prostate cancers (Varambally et al., 2002).  In 
support, EZH2 has been shown to function as a repressor of tumor suppressors (E-
cadherin and Slit2) in prostate cancer cells through trimethylation of h3k27 at their 
promoters (Fig. 1.8) (Cao et al., 2008; Yu et al., 2010a). The suppression of these genes 
has led to increased invasive capabilities of the prostate cancer cells (Cao et al., 2008; Yu 
et al., 2010a). The epigenetic silencing of DAB2IP expression by EZH2 was also 
demonstrated to enhance prostate cancer invasiveness through activating RAS and NFKB 
(Min et al., 2010). In addition, EZH2 was also implicated to play a role in maintaining an 
aggressive stem-cell-like state in prostate cancer cells by triggering a cellular de-
differentiation program through epigenetic silencing (Yu et al., 2010b; Yu et al., 2007b). 
Recent data suggests that EZH2 might play a role in AR-mediated repression of target 
genes (Zhao et al., 2012). However, no co-localization between EZH2 and AR on 
specific cis-regulatory elements was shown in the study to establish direct transcriptional 
collaboration between the two factors (Zhao et al., 2012). A genome-wide colocalization 
between AR and EZH2 that would clarify the generality of the transcriptional cross-talk 
would be beneficial for further insights. The results from Zhao et al. (Zhao et al., 2012)  
suggest the presence of an EZH2 and AR cross-talk in AR-mediated transcriptional 
repression but since the analysis is only limited to a few genes, it may not be 
representative of the exact nature of the cross-talk. Recent findings in the field have 
shown that the cross talk between AR and the transcriptional repressor, ERG, could 
promote prostate cancer progression through regulated suppression of AR signaling (Yu 
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et al., 2010b). Being a transcriptional repressor itself, EZH2 has the potential to facilitate 
prostate cancer development in a similar fashion as ERG, perhaps even through 
collaboration with ERG. Moreover, the expression levels of ERG and EZH2 were shown 
to be correlated in prostate cancers (Yu et al., 2010b). Accordingly, we think that further 











Figure 1.8 Examples of the Different Mechanisms of EZH2-mediated 
















1.12 Aims of Study  
 
As discussed above, various pieces of evidence have strongly linked the process of 
prostate cancer development to an alteration of the AR transcriptional output. The AR 
transcriptional output is a direct manifestation of the workings of the AR transcriptional 
circuitry. The AR transcriptional network exhibits high plasticity (Wang et al., 2009b). 
As such, prostate cancers are able to adapt, progress and recur through recalibration of 
the AR transcriptional circuitry. This could be accomplished via manipulating the 
expression levels of AR (Chen et al., 2004) and/or its transcriptional collaborators (Sahu 
et al., 2011; Wang et al., 2011). Hence, a thorough understanding of the cross-talk 
between AR and its collaborators could be useful to the development of new therapeutics 
for prostate cancers. 
In this study, we aim to investigate the transcriptional cross-talk between AR and the 
recurrent fusion gene, ERG. During the course of our work, other studies have provided 
evidence that ERG functions as an AR transcriptional collaborator that contributes to the 
development of prostate cancers by suppressing AR signaling (Sun et al., 2008; Yu et al., 
2010b). These independent studies, which are largely in agreement with our findings, 
have elucidated much insight about the AR and ERG crosstalk. However, these studies 
did not address the underlying mechanisms and functional consequences of the ERG-
mediated repression of AR signaling. Furthermore, as mentioned earlier in this thesis, 
apart from ERG, several other transcriptional repressors (HDACs and EZH2) were also 
shown to be over-expressed and had their expression levels correlated with ERG in 
prostate cancers. However, their potential involvement with the AR and ERG 
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transcriptional cross-talk remained unstudied. Utilizing genomic technologies and a 
variety of molecular biology techniques, we sought to characterize and analyze the AR 























CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Cell Culture 
 
LNCaP and VCaP, human prostate cancer cell lines were obtained from American Type 
Culture Collection (ATCC). Both are androgen dependent prostate cancer cell lines 
expressing functional AR protein. VCaP cells were maintained under 5% CO2 in DMEM 
solution supplemented with 10% fetal bovine serum (FBS), sodium pyruvate, sodium 
bicarbonate, and penicillin/streptomycin. LNCaP cells were also maintained under 5% 
CO2, but in RPMI medium 1640 supplemented with 10% FBS, sodium pyruvate, 
gentamycin and penicillin/streptomycin. Unless otherwise stated, VCaP cells were 
usually grown for 24 hrs prior to DHT (Tokyo Chemical Industry) stimulation, in phenol 
red free DMEM solution supplemented with 10% charcoal-dextran stripped fetal bovine 
serum (CDFBS), sodium pyruvate, sodium bicarbonate, and penicillin/streptomycin. 
LNCaP cells were usually cultured in phenol red free RPMI supplemented with 5% 
CDFBS, sodium pyruvate, gentamycin, and penicillin/streptomycin for 72 hrs prior to 
stimulation. For maintanence, the cells were subcultured once a confluency of 80% is 
reached (~5-7days).  
 
2.2 Fluoresence in-situ Hybridization (FISH) 
 
VCaP/LNCaP cells were treated with colcemide (10ug/ml) for 2 hrs prior harvesting. 
After which, the interphase and metaphase cells were prepared for FISH analysis by 
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fixation and standard hypotonic treatment. The cells were then treated with pepsin 
(100mg/ml) (Sigma) and HCl (0.01 mol/L) at 37°C (5 min) before fixation in 1% 
formaldehyde (Sigma) (10 min) and dehydration with a series of ethanol concentrations. 
Fosmid probes were obtained from the BACPAC Resource Center (BPRC, CHORI, 
Oakland, California, USA), and grown in accordance to the manufacturer’s protocols. 
DNA extraction was performed using Nucleobond PC500 (Macherey-Nagel) kit. 
Utilizing an Enzo Nick Translation DNA labeling system, the extracted DNA was labeled 
with either biotin-16-dUTP (Roche) or digoxigenin-11-dUTP (Roche). An estimated 
20ng of probe, together with 10ug of Cot1-DNA, was used per hybridization. The slides 
and probes mixes were codenatured at 75°C prior overnight hybridization at 37°C. Post 
hybridization washes were performed at 45°C and blocking was performed with blocking 
reagent (Roche). The slide was then incubated with avidin-conjugated fluorescein 
isothiocyanate (FITC) (Roche) and anti-Digoxygenin-Rhodamine (Roche). To enable 
visualization, the nuclei were stained by DAPI counterstain (Vector Laboratories). The 
fluorescence images were captured with a cooled charge-coupled device (CCD) camera 
attached to a Nikon fluorescence microscope using a 60X objective. The fosmid probe 
sequences utilized are shown in Appendix I. 
 
2.3 Chromatin Immunoprecipitation (ChIP) 
 
After starving, VCaP cells (24hrs) and LNCaP cells (72 hrs) were treated with 100nM 
DHT/EtOH for the indicated durations. Following that, the cells were fixed with 1% 
formaldehyde (Sigma-Aldrich, Missouri) prior collection. The harvested cell pellets were 
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then lysed with SDS lysis buffer (with Proteinase Inhibitor) and sonicated so as to shear 
the genomic DNA into lengths of 500-1000 bp. 3.33% (by volume) of the sheared 
chromatin was aliquoted and kept as input in -80
o
C fridge. The rest of the sheared 
chromatin was then precleared with normal rabbit IgG (Santa Cruz Biotechnology, Santa 
Cruz) and sepharose beads A (Zymed, San Francisco) for at least 2 hours in 4
o
C. After 
which, overnight immunoprecipitation was performed by incubating the precleared 
chromatin with the desired antibodies and sepharose beads A (Zymed, San Francisco). 
On the following morning, the beads were consecutively washed to remove non-specific 
bindings. After washing, the captured DNA-protein complex was eluted from the 
sepharose beads. De-crosslinking of the DNA from the DNA-protein complex was done 
at 65
o
C overnight. The de-crosslinked DNA was then purified with QIAquick spin PCR 
purification kit (Qiagen, California) and q-PCR quantified using the KAPA SYBR FAST 
qPCR kit with specific primers. DNA detection is performed with the ABI 7900HT Fast 
Real-Time PCR System. Primer Express (Applied Biosystems, California) was utilized 
for primer design (Appendix II). For HDAC1, HDAC2, HDAC3, and EZH2 ChIP, a 
double cross-linking strategy was utilized for the stabilization of protein-protein 
interactions. This would increase the pull-down efficiency of the DNA that are indirectly 
bound to these transcription factors. Specifically, cells were first fixed with 2 mM DSG 
(Pierce) for 45 minutes prior 1% formaldehyde fixation. Antibodies that were used for 
ChIP analysis are anti-AR (sc-815x), anti-ERG (sc-353), anti-HDAC3 (sc-11417) from 
Santa Cruz Biotechnology, anti-HDAC1 (ab7028-50), anti-HDAC2 (ab7029-50) from 




2.4 ChIP-Sequencing  
 
Altogether, 5ng of immunoprecipitated DNA from VCaP cells for each respective 
transcription factor was quantified using Pico-green ds DNA assay kit (Invitrogen) and 
used for ChIP-Seq library construction. The ChIP-Seq DNA sample Prep Kit (Illumina) 
was utilized for library preparation with some minor modifications. The ChIP DNA was 
made to undergo end-repair followed by adapter ligation. Platinum Pfx DNA polymerase 
(Invitrogen) was then used to amplify the ChIP-DNA. Electrophoresis of the amplified 
DNA products on a 2% agarose gel was subsequently performed. Detection of the 
amplified DNA products was done by staining the gel with SYBR® Green I Nucleic 
Acid Gel Stain (Invitrogen). DNA products of size 200-300bp were extracted by gel 
excision and purified. Confirmation of the size and quality of the extracted purified ChIP 
DNA was done using bioanalyzer prior sequencing on the Solexa platform. The 
sequencing depth for each library was at least 10million tags. ChIP-Seq read tags were 
aligned to the reference human genome (UCSC, hg18). The binding peaks were 
determined with CCAT (Xu et al., 2010) using input reads as control. To determine that 
the antibodies used for ChIP assays do recognize their intended target, validation was 
done with western blot assays using VCaP cells that were treated with siRNAs targeting 






Figure 2.1 Validation of ChIP antibodies 
Western blot analysis using VCaP cells treated with different siRNAs targeting different 
specific transcription factors. Probing was performed with respective matching ChIP 





















2.5 Western Blot Analysis 
 
VCaP/LNCaP cell pellets were harvested and lysed by vortexing in Triton X-100 at 4
o
C 
for 30mins. To determine the amount of protein for loading, protein quantification was 
done using Pierce BCA Protein Assay kit. The protein was denatured by boiling at 99
o
C 
in 4X SDS loading buffer (with mercaptoethanol) for 5 minutes prior separation by SDS 
polyacrylamide gel electrophoresis. After electrophoresis, the separated proteins were 
transferred to a nitrocellulose membrane, blocked at 37
o
C for 30mins with 5% milk and 
then incubated with adequate concentration of desired antibodies (primary and 
secondary). Protein bands were then detected using a chemiluminescent approach using 
ECL Plus (Amersham). The antibodies used for western blot analysis include anti-AR 
(sc-816), anti-ERG (sc-354), anti-Vinculin (sc-25336) from Santa Cruz, anti-AR 
(AR441) from Labvision, anti-HDAC1 (#05-100), anti-HDAC2 (#05-814) from 
Millipore, anti-HDAC3 (#3949) and anti-EZH2 (#3147) from Cell Signaling Technology.  
 
2.6 Co-Immunoprecipitation  
 
VCaP cells growing in full serum conditions were trypsinized and lysed to obtain whole 
cell lysate. A small aliquot of the whole cell lysate was first stored at -80°C. This aliquot 
was to be used as input during western blot analysis of the co-ip samples. After which, 
the rest of the cell lysate was pre-cleared with Protein A/G-Agarose beads (Roche 
Applied Science) for 4 hrs at 4
o
C. Post pre-clearing, the lysate was then incubated 
overnight with 5 µg of anti-AR (sc-815x), anti-ERG (sc-353) or anti-rabbit IgG as 
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required at 4°C. Protein A/G-Agarose Roche beads were added into the mixture on the 
following day and then further incubated at 4°C for another 1.5 hrs. After incubation, the 
agarose beads were washed with TBS for a total of four times so as to remove non-
specific binding. Finally, the beads were boiled for 5 minutes at 99°C prior being eluted 
with SDS loading buffer for western blot analysis. 
 
2.7 Short Interfering RNAs (siRNAs) 
 
Unless stated otherwise, a double knockdown approach was utilized for siRNA 
knockdown studies. VCaP cells seeded in a six well plate for 24 hrs were transfected with 
the selected siRNA at a concentration of 100 nM/transfection using 4ul of Lipofectamine 
RNAi Max (Invitrogen) twice with a 24 hours interval being observed between each 
transfection. For experiments requiring EtOH/DHT stimulation, the cells were starved, 
24hrs after the second transfection, in media containing CDFBS for another 24hrs. The 
siRNAs used in the study were siAR (ON-TARGETplus SMARTpool L-003400-00), 
siERG (SiGENOME D-003886-01), siHDAC1 (ON-TARGETplus SMARTpool L-
003493-00), siHDAC2 (ON-TARGETplus SMARTpool L-003495-00), siHDAC3 (ON-
TARGETplus SMARTpool L-003496-00), siEZH2 (ON-TARGETplus SMARTpool L-
004218-00) from Dharmacon, and siVCL synthesized from 1stBase. The siVCL sequence 
is rCrUrGrGrCrUrUrGrCrArGrArUrCrCrArArArUrUrU. The control siRNA for the 
siAR, siERG, siHDAC1/2/3 and siEZH2 experiments was from Dharmacon (D-001206-




2.8 Gene Expression Analysis 
 
Pre-treated VCaP/LNCaP cells were harvested and their total RNA collected in TRI-
reagent (Sigma). Purification of RNA was done with PureLink
TM
 RNA Mini Kit 
(Invitrogen) in accordance with the manufacturer’s protocol. Reverse transcription of 
RNA to cDNA was carried out using M-MLV reverse transcriptase (Promega). cDNA 
levels for specific genes were measured by quantitative PCR using the KAPA SYBR 
FAST qPCR kit and detected with the ABI 7900HT Fast Real-Time PCR System. All 
gene expression levels were normalized to GAPDH prior comparison. The primers for 
cDNA quantification were designed with Primer Express software (Applied Biosystems) 
and are listed in APPENDIX III.  
 
2.9 Microarray Expression Profiling 
 
In accordance with the manufacturer’s instructions, the purified total RNA from three 
independent biological replicates of VCaP cells, pre-treated with varying conditions (as 
stated), were converted to cRNA using the Illumina® TotalPrepTM-96 RNA 
Amplification Kit (Ambion). This was followed by hybridization of the synthesized 
cRNA onto Sentrix® HumanRef-8 v3 Expression BeadChip Kit (Illumina). The 
BeadChips were then scanned with the BeadArray Reader to obtain the image data that 
would be subsequently processed using GenomeStudio. Finally, the GeneSpring GX 11.0 




2.10 Matrigel Invasion Assay 
 
Invasion assay was performed with the HTS FluoroBlok Cell Culture Inserts (8.0 nm 
pore size) (BD). 750 l of media (with 20% FBS) was added into each well of a 24-well 
plate before the inserts were placed individually into each well. Each insert was first pre-
coated with 80 l of the pre-diluted (250 g/ml) Matrigel Basement Matrix (BD). 
Following which, the pre-knockdown cells (4 X 10
5 
siRNA-treated VCaP cells/2 X 10
5 
siRNA-treated LNCaP cells) that were already resuspended in 200 l media (with 0.5% 
FBS) were then seeded into each well respectively. The cells were then allowed to grow 
in the incubator for another 48 hrs prior harvested for assaying. During harvesting, the 
cells that invaded through the basement membrane and attached to the bottom of the 
inserts were fixed with 3.7% formaldehyde for 30 minutes. After fixation, the cells were 
then stained under dark conditions with 25 g/ml propidium iodide (PI) for 60 minutes. 
The was then used to scan, detect and count any cells that passed through the base 
membrane of the inserts. Ten different fields were taken for each insert for cell count 
averaging. Each condition was assayed in technical triplicates (three inserts for one 
condition) for biological triplicates. 
 
2.11 BrdU Assay for measuring Cell Proliferation 
 
BrdU assay was performed using the FITC BrdU Flow Kit (BD Pharmingen) in 
accordance with the manufacturer’s protocol. siRNA transfected VCaP cells growing in 
full serum were treated with BrdU (final conc. of 10uM)  for another 48hrs, 24hrs after 
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the second transfection, before harvested and fixed. The fixed cells were then 
permeabilized, re-fixed and incubated with DNAse for the cells to expose the 
incorporated BrdU. The exposed BrdU are then recognized and bound by the fluorescent 
anti-BrdU antibodies. Prior flow cytometry analysis, the cells were resuspended in 7-
AAD to stain for total DNA content for cell cycle analysis. The percentage number of 
cells in S phase was reported for 10000 cells. 
 
2.12 PI FACs Analysis for measuring Cell Survival 
 
The siRNA treated VCaP cells growing in full serum were harvested 48hrs after the 
second transfection, washed with PBS and subsequently fixed with 70% cold ethanol for 
45mins at 4
o
C. The fixed cells were then incubated at room temperature with RNAse 
(100ug/ml) for 5 mins. Following which, the cells were stained with 50ug/ml of 
propidium iodide for another hour in the dark. The percentage number of cells in sub G1 
phase was then detected through flow cytometry analysis of the genomic DNA content of 
10000 cells using the CellQuest Analysis software. 
 
2.13 Motif Discovery Analysis 
 
To find enriched DNA motifs around the ChIP binding peaks, the bioinformatic tools, 
MEME  (Bailey et al., 2009) and CentDist (Zhang et al., 2011) were utilized. The MEME 
program was used for the discovery of enriched DNA motifs in a de novo manner while 
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the CentDist program was used for finding the enrichment of known DNA motifs that are 
available in the TRANSFAC database (Wingender et al., 1996). 
 
2.14 Generation of Heatmap Binding Signals 
 
To generate the plot, ERG and ARBS that were within 500 bp of each other were 
clustered together. The AR and ERG libraries were re-sampled to 10 million tag reads 
and subsequently plotted out as intensity signals around a region of -/+2 kb centralized at 
the respective AR/ERG ChIP-Seq peak or AR/ERG clusters. Re-sampling was done to 
ensure a fair comparison of tag intensities between libraries. Individual binding region 
was then sorted according to their binding signal intensity at their respective categories 
(AR only, ERG only and AR/ERG overlap) for easy visualization.    
 
2.15 Conservation Analysis for Binding Peaks 
 
The conservation scores for the alignment of 27 vertebrate genomes with the Human 
genome (PhastCons28way) were downloaded from the UCSC Genome Browser 
database. The sequence conservation score of every nucleotide in a 2000 bp window 





2.16 Survival Curve Analysis 
 
Prostate cancer patient survival data and the gene expression profiles of their tumor 
samples were obtained from the MSKCC dataset available in this study (Taylor et al., 
2010). Patients were separated into two categories based on the expression levels of VCL 
in their tumor samples. Those expressing VCL levels higher than the median VCL 
expression level of all patients (in the dataset) were classified as high VCL expressing 
while the rest of the patients were classified as low VCL expressing. Survival association 
with VCL expression status (high/low) was computed using Cox-Proportional Hazards 
model implementation that is available in the R-library under ‘‘survival’’. Kaplan-Meier 
survival analysis was utilized for the analysis of the clinical outcome. 
 
2.17 Oncomine Concept Map and Gene Ontology Analysis 
 
The Oncomine Molecular Concept Map analysis was utilized for associating ERG-bound 
(5 kb from TSS) androgen induced genes (>2 fold) that were classified in this study with 
the defined prostate cancer gene signatures that were derived and deposited in the 
Oncomine database. Different nodes represent different sets of gene signatures and the 
size of the node proportional to the number of genes in that gene signature. The criteria 
for significant associations (represented as edges) between nodes is defined as Odds 




2.18 Data deposition 
 
The generated raw ChIP-Seq and gene expression profiling data in this study have been 























CHAPTER 3: RESULTS 
3.1 Confirmation of VCaP Cells as TMPRSS2-ERG Fusion Positive 
 
To study the AR and ERG transcriptional cross-talk, an ERG-fusion positive prostate 
cancer cell line would be necessary as a model system. The VCaP prostate cancer cell 
line was previously established as TMPRSS2-ERG fusion positive, resulting in ERG 
expression being induced by androgen stimulation (Tomlins et al., 2005). The FISH 
technique was utilized to validate the TMPRSS2-ERG fusion in VCaP cells (Fig. 3.1A). 
Indeed, through FISH, using probes that hybridize to the upstream and downstream 
region of the ERG gene loci separately, structural rearrangement was detected in the ERG 
gene locus of VCaP cells (some of the red and green probes were far apart) but not of 
LNCaP cells (all the red and green probes were co-localized). In addition, the presence of 
TMPRSS2-ERG fusion in VCaP cells (some of the red and green probes were co-
localised), but not in LNCaP cells (all of the red and green probes were far apart), was 
confirmed using probes that target the TMPRSS2 loci and the ERG loci respectively (Fig. 
3.1A). Furthermore, a time course profiling of both mRNA and proteins levels of ERG 
expression post DHT stimulation (Fig. 3.1B-C) indeed corroborates with previous 
published results that the ERG gene expression becomes transcriptionally induced by 
androgens as a result of the TMPRSS2-ERG fusion (Tomlins et al., 2005). As shown in 
Fig. 3.1B-C, DHT stimulation resulted in the repression of AR mRNA expression across 
time (Fig. 3.1B) with the protein level remaining relatively constant albeit exhibiting a 
slight decrease after prolonged DHT exposure (Fig. 3.1C). In contrast, the mRNA and 
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protein levels of ERG were both upregulated in response to androgen stimulation (Fig. 
3.1B-C). The prompt increment in ERG mRNA expression (6 hours) suggests a rapid 
initiation of AR mediated transcription upon androgen treatment. The observed 
difference in the androgen induced expression kinetics between ERG mRNA and proteins 
levels (peaking at 12 hrs for RNA and 24 hrs for protein) (Fig. 3.1B-C) is likely to be due 
to a lag time between transcription and translation. So far, the experiments have shown 
that VCaP prostate cancer cells could serve as a model experimental cell system for the 
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Figure 3.1 Androgen Regulated Expression of TMPRSS2-ERG Fusion Gene in 
VCaP cells 
(A) FISH validation of the presence of TMPRSS2-ERG fusion gene in VCaP cells. 
LNCaP cells were utilized as the negative control. Expression profiling analysis of AR 
and ERG (B) mRNA and (C) protein levels in VCaP cells after treatment with 10nM 







3.2 Binding Kinetic Analysis of AR and ERG to the Chromatin post 
Androgen Stimulation 
 
As AR-mediated transcription is likely to precede any increase in ERG protein levels post 
androgen stimulation, we sought to study the AR and ERG transcriptional cross-talk as a 
temporal event with regards to androgen signaling (Fig 3.2). The androgen induced 
recruitment of AR and ERG to the chromatin in VCaP cells was traced via a time-course 
AR/ERG ChIP at various durations (0hrs, 2hrs and 18hrs) post DHT stimulation. The 0 
hours time point is a representation of the unstimulated cell state. The 2 hours time point 
provides information on the transcriptional events arising during early androgen signaling 
while the 18 hours time point depicts late androgen signaling transcriptional events 
occurring after the increase in ERG protein expression. Post androgen stimulation, we 
observed strong early (2 hours) AR recruitment to the enhancer of the model AR target 
gene, PSA. This observation of strong early AR recruitment at the 2 hours time point is in 
concordance with our earlier conclusion that AR-mediated transcription could occur 
rapidly after DHT treatment. At the late phase of androgen signaling (18 hours), AR 
occupancy at the PSA enhancer persisted but was significantly reduced (Fig. 3.2). In 
comparison, ERG was also recruited to the PSA enhancer 2 hours post stimulation but 
unlike AR, whose binding was reduced at late phase of androgen signaling (18 hours), the 
recruitment of ERG remained strong (Fig. 3.2). Taken together, this set of results 
provides some evidence that AR and ERG could probably be co-localized on the 
chromatin together upon androgen stimulation but with different and distinct binding 
kinetics. Apart from the AR target gene, PSA, we also attempted to study the loading of 
ERG onto regulatory element unoccupied by AR. To this end, we performed an ERG 
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time course chip on the regulatory element of the ERG target gene, PLA1A. PLA1A was 
first established as a direct target of ERG and had its ERG-bound regulatory element 
identified in a previous study (Tomlins et al., 2008). Importantly, no significant AR 
occupancy was detected by our AR ChIP at this regulatory element (Fig. 3.2). We also 
observed a rise in ERG binding at this site during the late phase of androgen signaling (18 
hours) (Fig 3.2), possibly as a consequence of the increased ERG protein expression. As 
there was no significant increase in ERG protein levels at the early phase of androgen 
signaling (2 hours) (Fig. 3.1C), the recruitment of ERG to the PSA enhancer is likely to 













Figure 3.2 Kinetic Analysis of AR and ERG binding to Chromatin 
Hormone depleted VCaP cells were treated with 100nM DHT for different durations (0, 2 
or 18 hours) respectively prior formaldehyde cross-linking. The cross-linked chromatin 
was immunoprecipitated with antibody against either AR or ERG before quantifying with 
qPCR for selected binding sites. %input refers to % with respect to the total chromatin 
used for immuno-precipitation. Control (Ctrl) refers to a randomly selected genomic 













3.3 Generation of the AR and ERG Cistromes using ChIP-Seq  
 
To extend our earlier observations on the spatial and temporal characteristics of AR and 
ERG chromatin occupancy to a genome-wide scale in prostate cancer cells, several AR 
and ERG ChIP-Seq libraries at various time points post androgen stimulation (0, 2, 18 
hours) were generated (Table 3). Generally, substantial overlaps between AR and ERG 
cistromes, indicating the existence of a genome-wide transcriptional collaboration was 
observed (Fig. 3.3A). Interestingly, we noted that substantial overlap between AR and 
ERG cistrome was only observed after androgen stimulation as a result of a drastic 
increase in ARBS (Fig. 3.3A) after androgen stimulation. As expected, de novo motif 
analysis of the identified VCaP AR and ERG binding sites using MEME (Bailey et al., 
2009) reveals the presence of motifs that are strikingly similar to the canonical ARE and 
ETS-like sequence respectively (Fig. 3.3B). We also compared our work to a recently 
generated genome-wide map of AR and ERG in VCaP cells that was published in the 
course of our study (Yu et al., 2010b). Although the experimental conditions adopted in 
that study were different from ours, the cistromic maps generated in both studies still 
















Figure 3.3 The AR and ERG Cistromes in VCaP Cells 
A) Venn diagrams illustration of the overlap between AR and ERG cistromes in VCaP 
cells treated with 100 nM DHT for different durations (0, 2, 18 hrs). B) Weblogos of the 
most enriched motif found in AR and ERG binding sites respectively using the de novo 
motif discovery software, MEME (Bailey et al., 2009). C) Venn diagram illustration of 
the comparison between the AR and ERG cistromes in VCaP cells derived from this 
study and that of Yu et al., 2010b.   
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Library Name  FDR=0.05  FDR=0.1  FDR=0.2  Sequencing Depth (reads)  
ERG ChIP 0hr DHT  20545  23823  27474  13946853  
ERG ChIP 2hr DHT  24732  28579  34120  13075571  
ERG ChIP 18hr DHT  40229  41908  47725  15254728  
AR ChIP 0hr DHT  2004  2481  3137  12670989  
AR ChIP 2hr DHT  62297  68689  74834  15590194  
AR ChIP 18hr DHT  27882  33185  33958  11885706  
 
Table 3 Sequencing depth and peak numbers (under several FDR) of the different 
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3.4 Binding Kinetic Cistromic Profiles of AR and ERG under Different 
Phases of Androgen Signaling 
 
For a visual representation of the AR and ERG binding events, we plotted the binding 
profiles of AR and ERG centered on their binding clusters in a heatmap format (Figure 
3.4A). From the plot, we were able to make several interesting observations pertaining to 
the AR/ERG chromatin occupancy profiles in response to androgen signaling. Similar to 
our previous observation derived from individual loci (Fig. 3.2), the androgen-induced 
global kinetic binding profiles of AR and ERG were clearly distinct (Fig. 3.4A-B). 
Globally, there was minimal AR binding in the genome prior to any stimuli (Fig. 3.4A-
B). After a short period (2 hours) of DHT stimulation, AR was already strongly recruited 
to AR unique and AR+ERG co-localized sites across the genome. In concordance with 
the trend at PSA enhancer, there was a global reduction in AR occupancy at the late 
phase of androgen signaling (18 hours), an indication that the rate of AR recruitment is 
being outpaced by the rate of AR dissociation (Fig. 3.4A-B). Unexpectedly, for ERG, in 
contrast to AR, there was already a substantial amount of ERG preloaded at both ERG 
unique and AR+ERG co-localized binding sites prior to androgen induction (Fig. 3.4A-
B). We observed that while the binding of ERG at AR+ERG co-localized binding sites 
was generally enhanced after 2 hours of DHT stimulation, ERG binding at ERG unique 
binding sites remained mostly constant. This suggests the possibility that AR recruitment 
might be enhancing ERG loading at shared binding sites (Fig. 3.4A-B). ERG occupancy 
at the ERG unique sites eventually increased in the late phase of androgen signaling (18 
hrs) (Fig. 3.4A-B). This could be result of the presence of an increased level of ERG 
protein expression at that phase of androgen signaling. Interestingly, AR and ERG 
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consensus motifs were found strongly associated with the respective corresponding 
AR/ERG binding sites (Fig. 3.4A-B), suggesting that the presence of binding motifs is 
likely one of the major determinants of AR and ERG chromatin co-occupancy. We also 
made the observation that while ARBS harboring ERG are generally stronger AR binders 
than those that do not, ERG binding sites (ERGBS) that harbor AR did not display higher 
ERG tag intensities compared to their counterparts (Fig. 3.4C). This suggests that ERG 
tends to occupy stronger ARBS than weak ones (Fig. 3.4C (Left)) while AR exhibit no 

























          
Figure 3.4 Kinetic binding profiles of the AR and ERG cistromes under androgen 
signaling 
A) Heatmap display of sorted ChIP-Seq signals of AR and ERG chromatin occupancy 
events in VCaP cells. Signals are plotted in reference to the center of AR/ERG ChIP-Seq 
cluster peak (-/+2 kb). Corresponding occurrence of predicted ARE and ETS binding 
motif at the respective cluster peak are depicted in heatmap on the right. B) Plots showing 
the average AR and ERG ChIP-Seq tag counts at the different subsets of the AR and 
ERG binding cluster after 0, 2, and 18 hrs of androgen stimulation. C) A comparison of 
the average tag intensity of (Left) AR at AR unique and AR+ERG co-occupied binding 












3.5 Genomic Distribution and Sequence Conservation Analysis of AR 
and ERG Binding Sites 
 
We proceeded to examine the genome-wide distribution of AR/ERG binding sites. From 
our AR ChIP-Seq data, we noted that ARBS are mostly located at distal enhancers far 
away from the transcriptional start sites (TSS) of genes rather than at proximal promoters 
(Fig. 3.5A). This is consistent to what was previously reported about ARBS at 
chromosomal level (Wang et al., 2007). In comparision, ERGBS were found substantially 
at both promoter proximal and distal locations. For AR and ERG co-localized sites, they 
were also located at sites distal to the TSS, a distribution similar to AR unique binding 
sites (Fig. 3.5A). From evolutionary sequence conservation analysis, we found the peaks 
of AR and ERG binding sites to be generally conserved as they display higher 
conservation score relative to their flanking regions (background) (Fig. 3.5B). ERG 
unique binding sites were noted to exhibit the highest conservation score relative to AR 
unique and AR+ERG co-occupied binding sites (Fig. 3.5B). This is probably as a result 
of a large proportion of ERGBS being localized to the generally highly conserved TSS of 
genes. On the other hand, AR+ERG overlapping binding sites were generally more 
conserved when compared to AR unique binding sites (Fig. 3.5B), suggesting that these 
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Figure 3.5 Genomic Distribution and Sequence Conservation Analysis 
A) Genome-wide distribution of AR and ERG occupied sites with respect to the 
transcription start sites (TSSs) of RefSeq genes. (B) Conservation sequence analysis of 





3.6 The Transcriptional Collaborative Nature of AR and ERG 
 
3.6.1 Interplay between ERG and AR 
 
Basing on the substantial global co-occupancy of AR and ERG at cis-regulatory 
elements, we postulate the existence of a genome-wide transcriptional crosstalk between 
AR and ERG. Strikingly, we observed strong co-localization of AR and ERG at 
important regulatory elements of AR model target genes such as PSA and FKBP5 (Fig. 
3.6A). As a further support for the direct collaboration between AR and ERG, an 
endogenous interaction between AR and ERG was detected through immunoprecipitation 
(Fig. 3.6B). Interestingly, apart from occupying AR-bound enhancers, ERG occupancy 
was also enriched at the promoters of AR target genes identified from our time course 
microarray experiments (Fig. 3.6C and Fig. 3.6D). Interestingly, we observed that the 
ERG binding at these gene promoters are generally not influenced by androgen 
stimulation (Data not shown). These findings point to an extensive interplay between 
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Figure 3.6 AR and ERG Cross-Talk  
A) Snapshots of AR and ERG binding sites at two of the model AR target genes: (Top) 
PSA and (Bottom) FKBP5. The black arrows indicate the position of the co-localized AR 
and ERG binding sites. B) Western blot analsysis depicting endogenous interactions 
between AR and ERG in VCaP cells. C) Androgen deprived VCaP cells treated with 
10nM DHT/vehicle (EtOH) for the specified durations were harvested for total RNA. 
Gene profiling was subsequently performed. Fold change represents ratio of gene 
expression under DHT stimulation to their respective expression under vehicle (EtOH) 
stimulation. 3 independent repeats were performed. D) Bar graphs depicting the 
percentage of genes with an ERG occupied promoter. Androgen regulated genes are 










3.6.2 Androgen Induced Transcriptional Programs Regulated by Distinct 
Subsets of AR Cistrome  
 
To examine the androgen-mediated transcriptional programs regulated by AR unique and 
AR+ERG binding sites respectively, we performed a gene ontology analysis using 
Ingenuity systems Pathway Analysis (IPA) on identified androgen-regulated genes 
associated with AR unique or AR+ERG binding sites. We observed that while AR+ERG 
binding sites were more associated with genes responsible for cellular movement, growth 
and proliferation as well as cell cycle and morphology, AR unique binding sites were 
more associated with genes related to cell death (Fig. 3.7). Taken together, our results so 
far indicate that AR and ERG binding across the genome shares a large overlap but yet 










Figure 3.7 IPA analysis of genes associated with AR unique or AR+ERG 













3.6.3 Microarray Profiling of Androgen Regulated Genes after ERG 
Depletion 
 
To investigate the nature of this cross-talk, we assessed the effect of siRNA-mediated 
ERG silencing on androgen regulated AR target genes. Intriguingly, we found that ERG 
depletion in VCaP cells (Fig. 3.8A) culminated into a further induction of androgen 
upregulated model target genes such as PSA and FKBP5 (Fig. 3.8B). This result suggests 
that ERG could function to repress androgen signalling. To assess if the extent of the 
repressive effect of ERG on androgen signalling, we went further on to perform a 
microarray profiling of androgen regulated genes after ERG knockdown in VCaP cells 
(Fig. 3.8C). We noted that ERG silencing affects both androgen up and down regulated 
genes. Expectedly, we found that ERG knockdown indeed led to the enhancement of the 
expression levels of a substantial set of androgen-upregulated genes (393). This implies 
that attenuation of AR signaling is probably one of the major transcriptional processes 











       
 











Figure 3.8 Effect of ERG silencing on androgen induced gene transcription 
A) AR and ERG expression levels in androgen deprived VCaP cells that were transfected 
with control siRNA or siRNA against AR/ERG prior stimulation with EtOH/10 nM DHT 
for 18 hrs. GAPDH was utilized as loading control. B) Androgen deprived VCaP cells 
were first transfected with control siRNA or siRNA targeting AR/ERG. After 8 hrs of 
EtOH/ 10 nM DHT stimulation, cells were then harvested for total RNA. The total RNA 
was converted to cDNA for quantification with qPCR. GAPDH was utilized as a control 
for internal normalization. Error bars represent S.E.M of at least 3 independent 
experiments. C) Heatmap representation of gene profiling data. VCaP cells that were 
transfected with control siRNA or siRNA targeting ERG were subsequently deprived of 
androgens prior stimulation with ETOH/10 nM DHT for 8 hrs. Cells were then harvested 
for total RNA and utilized for microarray analysis. Genes that exhibited at least 1.5 fold 
alteration after DHT stimulation (Ctrl+) (relative to vehicle (Ctrl-)) were filtered as 
androgen responsive genes. Genes that displayed at least 1.2 fold change after ERG 
depletion (ERG+) (relative to control siRNA treated with DHT (Ctrl+)) were regarded as 
affected by ERG knockdown. The numbers of genes in the different groups after ERG 




3.6.4 ERG Depletion Enhanced AR Recruitment to the Chromatin 
 
We proceeded to examine the possible mechanisms underlying of ERG-mediated 
attenuation of androgen-dependent transcription.  We postulated that ERG knockdown 
could enhance AR binding and in turn induce higher AR-target gene expression. To test 
if ERG suppresses AR recruitment to the chromatin, we performed AR ChIP in VCaP 
cells after ERG depletion. Depletion of ERG resulted in a significant rise in AR binding 
at multiple tested AR+ERG occupied binding sites including those ARBS that are 
associated with PSA and FKBP5 (Fig. 3.9A and 3.9B). To assess the effect of ERG 
depletion on genome-wide AR binding, we examined the AR ChIP-Seq dataset recently 
generated by another group (Yu et al., 2010b) in ERG knockdown VCaP cells. Their data 
suggest that ERG silencing could result in a gain of new AR binding sites (Fig. 3.9C). 
Taken together, our results and those of another (Yu et al., 2010b) suggest that the 
repressive influence of ERG on AR induced transcription could be attributed, at least in 
part, to the reduction of AR binding to its cis-regulatory elements, possibly as a result of 




















                                  
Figure 3.9 ERG Depletion Induce AR Recruitment to the Chromatin  
A) and B) VCaP cells transfected with control siRNA or ERG targeting siRNA were 
deprived of androgens for 24 hours prior a 2h stimulation with EtOH/100 nM DHT. ChIP 
assays were performed using antibodies against AR. The immunoprecipitated DNA was 
quantified with qPCR. Error bars represent S.E.M of at least 3 independent biological 
repeats. C) The overlap of AR cistromes in VCaP cells treated with control siRNA or 
ERG targeting siRNA under normal full serum condition. The ChIP-Seq datasets were 






















3.7 Involvement of HDACs and EZH2 in AR and ERG Transcriptional 
Cross-talk. 
 
3.7.1 Overexpression of HDACs and EZH2 in Prostate Cancer 
 
As discussed in the introduction, several transcriptional co-repressors (the histone 
deacetylases (HDAC1, HDAC2, and HDAC3) and the methyltransferase EZH2) were 
known to be widely overexpressed in prostate cancers (Fig. 3.10). Although these co-
repressors were shown to play important roles in the progression of prostate cancers (Min 
et al., 2010; Wang et al., 2009a; Yu et al., 2010a; Yu et al., 2007b), their relationship with 
AR and ERG cross-talk is virtually unknown. Interestingly, the expression of these co-
repressors was recently demonstrated to exhibit a positive correlation to ERG levels (Iljin 
et al., 2006; Yu et al., 2010b) in clinical prostate cancer samples. Furthermore, ERG-
fusion positive prostate cancer cells were shown to exhibit enhanced sensitivity to HDAC 
inhibitors (Bjorkman et al., 2008). Basing on these observations, we postulate a potential 
direct collaboration between these co-repressors and ERG in suppressing AR 




Figure 3.10 Overexpression of HDACs and EZH2 in Prostate Cancer 
Boxplots of the relative mRNA expression levels of the transcriptional co-repressors 
HDAC1, HDAC2, HDAC3 and EZH2, in clinical prostate samples from the Yu’s (Yu et 













3.7.2 Chromatin Occupancy of HDACs and EZH2 at ARBS 
 
Both HDACs and EZH2 are transcriptional factors that are usually recruited to the 
chromatin and subsequently exert their repressive influence via modifying the histone 
tails. Hence, to validate our hypothesis that these co-repressors directly participate in the 
ERG-mediated suppression of AR transcriptional activity, we first tested their 
recruitment to AR+ERG binding sites by performing ChIP assays for these factors in 
VCaP cells before and after androgen stimulation. In support of our postulation of a 
transcriptional collaboration, we found that HDAC1, HDAC2, HDAC3, and EZH2 were 
all recruited to several AR + ERG co-localized binding sites including those that were 
associated with PSA and FKBP5 (Fig. 3.11A). Interestingly, we observed that androgen 
actually stimulate the recruitment of these corepressors in most cases, suggesting that this 
transcriptional co-operation is under the regulation of androgen signaling (Fig. 3.11A). 
Next, we proceeded to investigate the binding kinetics of HDACs and EZH2 with 
reference to AR and ERG recruitment to the chromatin, we peformed time-course ChIP 
assays at a series of timepoints upon androgen stimulation. We observed that similar to 
AR, HDAC1-3 and EZH2 were recruited to the several tested AR + ERG co-localized 
binding sites shortly (as early as 15 mins) after androgen stimulation (Fig. 3.11B). 
Furthermore, the binding profiles of HDAC1-3 and EZH2 overlapped substantially to that 
of AR and ERG, suggesting a link between the recruitment of AR and ERG with that of 
HDAC1-3 and EZH2 (Fig. 3.11B). To further establish the transcriptional co-operation 
between AR and ERG with HDAC1-3 and EZH2, we performed co-immunoprecipitation 
to probe for any endogenous physical interactions that would provide further evidence for 
a direct collaboration between these transcription factors. Indeed, we were able to detect 
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physical endogenous interactions between HDAC1, HDAC2 and EZH2 with both AR 
and ERG (Fig. 3.11C). However, intriguingly, we were unable to detect any interaction 
between HDAC3 with either AR or ERG from our co-immunoprecipitation assays. We 
reckoned that this might be a result of a much weaker and/or more transient interaction 
between HDAC3 with AR or ERG.  Integrated together, our results suggest that HDACs 









































                                
 
Figure 3.11 Physical Interaction and chromatin co-occupancyof HDACs and EZH2 
with AR and ERG  
A) VCaP cells were starved in androgen-free media for 24 h prior treatment with 
EtOH/100 nM DHT for 2 h. Subsequently, the cells were first double crosslinked with 
DSG followed by formaldehyde fixation. Immunoprecipitation was carried out with 
antibodies against HDAC1, HDAC2, HDAC3, or EZH2. qPCR quantification was 
performed for specific binding sites. Error bars are indicative of S.E.M for at least 3 
independent experiments. B) Time course ChIP assays for the indicated DHT stimulated 
timings for AR, ERG, HDAC1-3 and EZH2 in VCaP cells were performed as described 
in (A). C) Western Blot analysis showing the results of the AR/ERG co-
immunoprecipitation assays that were performed for probing endogenous interactions 












3.8 Cistromic Analysis of HDACs and EZH2 in VCaP Cells 
 
3.8.1 Motif and Location Analysis of HDACs and EZH2 Cistromes 
 
To further establish the extent of transcriptional collaboration between AR, ERG and the 
corepressors, HDACs and EZH2 on androgen signaling, we went on to generate the 
cistromes of these factors in VCaP cells prior and after (2 hrs) DHT stimulation (Table 
4). The 2 hrs time-point was chosen as it corresponds to the largest overlap in AR and 
ERG co-localized binding from our earlier studies (Fig. 3.3A). Using the in-house 
generated bioinformatic tool, CENTDIST (Zhang et al., 2011), which detects motifs 
enriched in a set of DNA sequence, we found good center of distribution scores for both 
AR and ERG binding motifs at HDAC2, HDAC3, and EZH2 binding sites. This means 
these transcription factors are generally recruited to the DNA at a position that is near the 
AR and ERG binding motifs, suggesting a potential indirect recruitment via tethering to 
AR and ERG (Fig. 3.12A). Accordingly, since only ERG motifs were found enriched for 
HDAC1 binding peaks, this might be an indication that the recruitment of HDAC1 is 
occurring mainly through ERG. Next, we examined the location genomic distribution of 
the corepressors. HDAC1 was found to have a high binding preference to promoters, 
while HDAC2 and HDAC3 were mostly found at distal enhancers (Fig. 3.12B). From 
past studies, it was generally assumed that EZH2 was mainly recruited to the promoter 
regions to regulate transcription (Ku et al., 2008; Margueron et al., 2008; Yu et al., 
2007a), but data from our EZH2 cistromic analysis surprisingly revealed that EZH2 is 
actually found substantially at distal enhancers in prostate cancer cells during androgen 
signaling (Fig. 3.12B). This was an intriguing finding that suggests a novel 
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transcriptional role for EZH2. To validate the authenticity of our generated cistromic 
maps and the co-localization of the co-repressors (HDACs1-3 and EZH2) with AR and 
ERG, we performed ChIP-qPCR validation of all these co-repressors for multiple 

































Figure 3.12 Motif and Location Analysis of HDACs and EZH2 Binding Sites 
A) The binding sites of each respective co-repressor were input into the CentDist 
program. The generated average tag count distribution of Androgen Response Elements 
(AREs) and ETS binding motif (ETS) relative to the peaks of the respective co-repressor 
binding sites is displayed in graphical form. B) Bar chart showing the proportion of 
binding sites located at the promoter proximal (-/+3 kb from TSS) or distal regions for 
AR, ERG, HDAC1, HDAC2, HDAC3, and EZH2 respectively. C) VCaP cells were 
depleted of androgens and treated with either ETOH/100 nM DHT for 2 hrs. Chromatin 
Immunoprecipitation was carried out as described in Fig 3.11A with antibodies against 
AR, ERG, HDAC1, HDAC2, HDAC3, or EZH2. Immunoprecipitated DNA was 
quantified with qPCR for the specified AR+ERG co-occupied sites. Error bars represent 









EtOH  0 0 1925 24944881 
HDAC1 ChIP 
DHT  0 614 3434 25133481 
HDAC2 ChIP 
EtOH  11288 16581 24309 14508414 
HDAC2 ChIP 
DHT  10500 19813 25669 19626271 
HDAC3 ChIP 
EtOH  0 1785 3667 23135520 
HDAC3 ChIP 
DHT  1664 3225 5311 23350682 
EZH2 ChIP EtOH  516 1336 1677 25434932 
EZH2 ChIP DHT  815 1559 2794 24458897 
 
Table 4 Sequencing depth and peak numbers (under several FDR) of HDAC1-3 and 















3.8.2 Characterization and Analysis of the AR-Centric Co-repressor 
Regulatory Transcriptional Network in ERG-fusion Positive VCaP Cells 
 
In concordance with our hypothesis that ERG, HDAC1-3 and EZH2 are widely involved 
in the direct regulation of androgen induced transcription, our cistromic studies of AR, 
ERG and the co-repressors  revealed an intricate AR-centric transcription network in 
which the co-repressors are  integrated into the network via occupation of different 
subsets of the AR and ERG cistromes with varying binding kinetics. In addition, the 
integration of these co-repressors is strongly enhanced on androgen signaling, suggestive 
of a feedback mechanism. We noted distinct combinations of corepressor recruitment in 
relation to AR and ERG binding sites. Both AR+ERG co-localized and AR unique 
binding sites are largely occupied by HDAC2, HDAC3, and EZH2 but the strength of the 
recruitment to AR unique sites was of a much weaker degree (Figs. 3.13A and 3.13B). In 
comparison, at ERG unique binding sites, we only observed HDAC1 and 2, but not 
EZH2 occupancy (Figs. 3.13A and 3.13B). Interestingly, we found that recruitments of 
HDAC2, HDAC3 and EZH2 to ARBS sites were enhanced upon androgen stimulation 
while no changes in HDAC1 binding were observed at the same binding sites. The 
strongest (average ChIP-Seq tag count) recruitment of these factors was observed at 




























Figure 3.13 Characterization of the HDAC1-3 and EZH2 Cistrome in relation to AR 
and/or ERG Binding sites on Androgen Signalling 
A) Heatmap representation of sorted normalised ChIP-Seq tag count of AR, ERG, 
HDAC1, HDAC2, HDAC3 and EZH2 binding, centralized on the center of AR and/or 
ERG ChIP-Seq peak (-/+2 kb) in VCaP cells. (B) Graphical display of the average ChIP-
Seq tag count intensities of AR, ERG, HDAC1, HDAC2, HDAC3, and EZH2 at different 










3.9 Attenuation of Androgen Induced Transcription by HDACs and 
EZH2 in ERG-Fusion Positive VCaP Cells 
 
So far, our observation of the genome-wide recruitment of HDACs and EZH2 to 
AR+ERG co-localized binding sites across the prostate cancer genome strongly suggests 
the participation of these co-repressors in ERG-mediated attenuation of androgen-
dependent transcription. Consistent with this observation, we found co-localization of 
HDACs and EZH2 at AR+ERG co-occupied transcriptional regulatory elements of PSA 
and FKBP5, model androgen induced direct target genes that are repressed by ERG (Fig. 
3.14A). To determine the role HDACs and EZH2 in androgen-dependent transcription, 
we utilized specific small molecule inhibitors that block the activity of these co-
repressors and examined its effects on the androgen-induced transcript levels of PSA and 
FKBP5. Specifically, TSA and DZNep were used to inhibit the activities of HDACs and 
EZH2 respectively. Interestingly, androgen-induced transcript exhibited a biphasic 
transcriptional response to TSA treatment: at low concentrations, TSA enhanced PSA and 
FKBP5 transcript levels but was repressive at high concentrations. This suggests a dual 
(activation and repression) role for HDACs in regulating AR transcriptional activity (Fig. 
3.14B). As for DZNep, we observed enhancement in the expression of both PSA and 
FKBP5 after treatment, consistent with a role for EZH2 in repressing AR transcriptional 
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Figure 3.14 Co-recruitment of HDACs, and EZH2 to AR+ERG occupied sites 
repressed AR-dependent transcription  
(A) Snapshots of HDAC1, HDAC2, HDAC3, and EZH2 at AR+ERG occupied 
regulatory elements of model AR target genes, PSA and FKBP5. (B) VCaP cells grown 
in full serum (top) or starving medium were co-treated with vehicle/10 nM DHT (bottom) 
and varying concentrations of TSA for 24 hours. After which, total RNA from the cells 
were extracted and converted to cDNA. The transcript levels were quantified by qPCR 
using GAPDH as an internal normalization control. Error bars represent S.E.M of at least 
3 independent experiments. (C) VCaP cells grown in full serum (left) or starving medium 
treated with vehicle/10 nM DHT for 8 hours (right) were first subjected to vehicle/3 M 
DZNep stimulation for 24 (left) or 48 (right) hrs. Total RNA was harvested and 









3.10 Roles of HDACs and EZH2 on Androgen Induced Transcription in 
ERG-Fusion Negative LNCaP Cells 
 
Thus far, we have only investigated the role of HDACs and ERG in AR-mediated 
transcription using the ERG overexpressing VCaP prostate cancer cells. Since there has 
been no evidence suggesting that the overexpression of HDACs and EZH2 in prostate 
cancer is exclusively limited to ERG-fusion positive subtypes, we questioned if these co-
repressors played similar roles in ERG-fusion negative prostate cancer with little or no 
ERG expression. To address this question, we examined the effects of HDACs and EZH2 
on AR-dependent transcription in LNCaP cells (an AR-positive but ERG negative 
prostate cancer cell line). Earlier, we observed that unlike VCaP cells, LNCaP cells do 
not harbor the TMPRSS2-ERG fusion (Fig. 3.1A). We further demonstrated that there is 
negligible ERG expression in LNCaP relative to VCaP (Fig. 3.15A). In addition, we 
compared the expression levels of AR, HDAC1-3 and EZH2 between the two cell lines. 
From our results, we noted that apart from not expressing ERG, the expression levels of 
AR and HDAC3 was also significantly lower in LNCaP as compared to VCaP (Fig. 
3.15A). The extremely high level of AR in VCaP was within our expectations as AR is 
known to be highly amplified in VCaP cells (Liu et al., 2008).  On the other hand, the 
expression levels of EZH2, HDAC1 and HDAC2 was similar in both LNCaP and VCaP 
cells (Fig. 3.15A). We then tested the recruitment of these transcription factors via ChIP 
assays. Interestingly, we found that in LNCaP cells, HDACs and EZH2 were also 
recruited after androgen stimulation, similar to the ARBS that were earlier tested in VCaP 
cells (Fig. 3.11A) but their binding affinities, were in most instances, lower (with respect 
to % input) than VCaP cells (Fig. 3.15B). Within expectations, while AR was 
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significantly recruited to the ARBS tested, negligible ERG recruitment was detected (Fig. 
3.15B). Next, we assessed the role of HDACs and EZH2 on AR-mediated transcription in 
LNCaP cells. LNCaP cells were treated with small molecule inhibitors of HDACs or 
EZH2 (TSA or DZNep). We found that there was a much weaker (compared to LNCaP) 
or no response in androgen upregulation of model AR target genes such as PSA and 
FKBP5 after treatment with DZNep and TSA, respectively (Fig. 3.15C). Taken together, 
while our results are suggestive towards the conclusion for a more pronounced role of 
HDACs and EZH2 in the repression of AR activity under an ERG-fusion positive 
prostate cancer system such as VCaP cells, further experiments are required for 



































                        
Figure 3.15 Role of HDACs and EZH2 on AR-mediated Transcription in ERG-
Fusion Negative Prostate Cancer Cells 
A) Western Blot analysis probing for AR, ERG, HDAC1-3 and EZH2 in androgen 
deprived LNCaP and VCaP cells after 2 hrs of 100nM DHT/EtOH stimulation. B) 
Androgen-depleted LNCaP cells were treated for 2 hrs with ETOH/100 nM DHT. 
Chromatin was immunoprecipitated with specific antibodies against AR, ERG, HDAC1, 
HDAC2, HDAC3, or EZH2 using the same procedures as those for VCaP cells (Fig 
3.11A). Immunoprecipitated DNA was quantified through qPCR. Error bars represent 
S.E.M of at least 3 independent experiments. C) (Left panels) Hormone depleted LNCaP 
cells co-treated with vehicle or 10 nM DHT were subjected to varying concentrations of 
TSA for 24 hrs as for VCaP cells in Fig 3.14B (bottom). (Right panels) Hormone 
depleted LNCaP cells were pre-treated with vehicle or 3μM DZNeP for 48 hrs and then 
subjected to with or without 10 nM DHT for 8 hrs as for VCaP cells in Fig 3.14C (right). 
Total RNA from the treated cells were then harvested and converted to cDNA before 
quantifying for gene expression levels. GAPDH was used as an internal normalization 






3.11 The Role of ERG in AR-Directed Prostate Cancer Progression 
 
ERG was suggested to inhibit differentiation, expedite (Epithelial Mesenchymal 
Transition) EMT and promote metastasis in prostate cancer cells through direct 
transcriptional upregulation of genes such as PLA1A, PLAT, PLAU, and EZH2 (Tomlins 
et al., 2008; Yu et al., 2010b). Apart from being a transcriptional activator, our findings 
indicate that ERG also functions as a repressor of AR-dependent transcription, possibly 
by working together with corepressors such as HDACs and EZH2. However, it is still 
unclear as to whether if ERG can promote prostate cancer progression through the direct 
suppression of AR-mediated transcription. To assess the clinical importance of ERG 
inhibition on AR-dependent transcription in prostate cancer development, we performed 
an Oncomine molecular concept map (MCM) analysis with androgen-upregulated genes 
that are associated with ERGBS using data of clinical prostate samples deposited in the 
Oncomine database. From the analysis, we observed ERG bound androgen induced genes 
to be associated with several concepts related to prostate cancer, especially with those 
concepts depicting genes that are over-expressed in primary cancer (compared to normal 
prostate) but repressed in advanced and metastatic prostate cancer (compared to primary 
prostate cancer) (Fig. 3.16A and Table 5). This result implied the occurrence of reduced 
androgen signaling in aggressive forms of prostate cancer during prostate cancer 
progression. Interestingly, this finding was corroborated by a recent study that was 
published in the course of this work (Yu et al., 2010b) by another group using their own 
defined target gene signature but with a similar methodology. To further support the 
validity of this claim, we performed an additional analysis on the clinical prostate cancer 
dataset of a very extensive clinical study (Taylor et al., 2010) and also observed similar 
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findings (Fig. 3.16B). Again, the same set of defined androgen induced genes was found 
to exhibit significantly higher expression levels in primary prostate tumors (compared to 
normal prostate) albeit lower expression levels in metastatic prostate tumors (compared 



























Figure 3.16 Expression Profiles of ERG associated Androgen Induced Gene Set in 
Clinical Prostate Samples 
A) A network display of clinical prostate cancer gene signatures that have a significant 
correlation with the ERG-associated androgen upregulated gene set defined in this study. 
The Oncomine Molecular Concept Map (MCM) analysis was utilized to compare defined 
ERG-associated (5 kb from TSS) androgen induced genes (>2 fold) against clinical 
prostate cancer gene signatures depositied in the Oncomine database. Criteria for 
establishing significant associations between node is defined as OD≥2; p-value < 1e-4. B) 
Boxplot displays of the average normalised expression for each individual gene in the 
defined androgen induced gene signature under respective category of clinical prostate 
sample. ERG-associated androgen induced gene signature were identified as described in 
Fig. 3.16A. Using the normalized MSKCC prostate cancer clinical dataset (Taylor et al., 
2010), the average expression of each gene in the androgen induced gene signature for 
each sample type was assessed and plotted. Normalization is done by log transformation 
of the expression of each probe and then subtracting by probe median. The mean of the 
expression of each probe in the respective category is then plotted out in box plot form. 
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Concept Name  P-value  
Odds 
Ratio  
Cancer Type: Prostate Cancer - Top 10% Over-expressed (Bittner Multi-cancer)  1.17E-32  5.1  
Prostate Adenocarcinoma - Advanced Gleason Score - Top 10% Under-expressed 
(Vanaja Prostate)  2.22E-22  4  
Prostate Carcinoma vs. Normal - Top 10% Over-expressed (Welsh Prostate)  8.57E-22  5.3  
Prostate Carcinoma Epithelia - Advanced Gleason Score - Top 5% Under-expressed 
(Tomlins Prostate)  1.89E-19  5.9  
R1881 Treatment + Vector Only Transfection Control - LNCaP Cell Line - Top 10% 
Over-expressed (Chen CellLine)  1.02E-13  3.3  
Benign Prostatic Hyperplasia Tissue Subtype - Epithelia - Top 10% Over-expressed 
(Tomlins Prostate)  3.49E-13  3.6  
Cancer Type: Prostate Cancer - Top 10% Over-expressed (Ramaswamy Multi-cancer)  1.25E-11  3.3  
Prostate Carcinoma vs. Normal - Top 5% Over-expressed (Singh Prostate)  1.89E-10  4.3  
Prostate Carcinoma - Advanced Gleason Score - Top 10% Under-expressed (Yu 
Prostate)  1.92E-10  3.3  
Amsacrine Sensitive - Multi-cancer Cell Line - Top 10% Under-expressed (Compendia 
CellLine)  2.32E-09  2.7  
Prostate Adenocarcinoma - Smoker - Top 10% Under-expressed (Wallace Prostate)  2.32E-09  2.7  
Prostate Carcinoma Primary Cell Culture - Recurrence at 1 Year - Top 10% Under-
expressed (Nanni Prostate)  6.32E-09  2.6  
Cancer Type: Prostate Cancer - Top 10% Over-expressed (Su Multi-cancer)  1.77E-08  2.9  
Cancer Type: Prostate Cancer - Top 10% Over-expressed (Ramaswamy Multi-cancer 2)  8.08E-08  2.6  
Prostate Adenocarcinoma vs. Normal - Top 10% Over-expressed (Vanaja Prostate)  1.55E-07  2.3  
Prostate Cancer - Metastasis - Top 10% Under-expressed (Varambally Prostate)  4.72E-07  2.2  
Benign Prostatic Hyperplasia Epithelia vs. Normal - Top 10% Over-expressed (Tomlins 
Prostate)  7.77E-07  2.5  
Prostate Carcinoma - Advanced Gleason Score - Top 5% Under-expressed (Lapointe 
Prostate)  1.01E-06  2.9  
Prostate Carcinoma Primary Cell Culture - Advanced Gleason Score - Top 10% Under-
expressed (Nanni Prostate)  3.67E-06  2.2  
Prostate Carcinoma vs. Normal - Top 1% Over-expressed (Varambally Prostate)  9.31E-06  4.8  
Prostate Adenocarcinoma - Advanced Gleason Score - Top 10% Under-expressed 
(Wallace Prostate)  1.82E-05  2.1  
Topotecan Sensitive - Cell Line - Top 5% Under-expressed (Gyorffy CellLine)  2.39E-05  2.5  
Prostate Carcinoma - Recurrence at 5 Years - Top 10% Over-expressed (Holzbeierlein 
Prostate)  2.58E-05  2.8  
Prostate Cancer - Metastasis - Top 10% Under-expressed (Lapointe Prostate)  3.67E-05  2.1  
Acinar Prostate Adenocarcinoma - Smoker - Top 5% Under-expressed (Bittner Prostate)  3.77E-05  2.3  
 
Table 5 List of Oncomine concepts significantly associated with the defined ERG-
targeted androgen-induced gene signature 
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3.12 ERG-mediated Attenuation of Androgen Induced Epithelial 
Cytoskeletal Proteins that are associated with an Epithelial Phenotype. 
 
Results derived from our analysis on available clinical data (Fig. 3.16A and Fig. 3.16B) 
are suggestive towards the conclusion that regulated repression of a significant portion of 
ERG-associated androgen induced genes facilitate the progression of prostate cancers to 
the advanced and metastatic forms. As discussed in the introduction, although ERG 
repressed androgen induced targets like PSA and FKPB5 are markers of epithelial 
differentiation; they have no known functional role in driving metastasis and cancer 
progression. Interestingly, a detailed examination of the ERG-associated androgen 
induced genes elucidated previously reported mediators of Mesenchymal to Epithelial 
Transition (MET) (a process that reduces metastasis) in breast cancer. Examples include 
KRT8 and KRT18 (Buhler and Schaller, 2005; Tomaskovic-Crook et al., 2009) (Fig. 
3.17A). qPCR confirmed the androgen induced upregulation in the expression of these 
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Figure 3.17 Transcription Regulation of Keratin Genes by AR and ERG  
A) ChIP-Seq dervived snapshot of AR and ERG binding events near KRT8 and KRT18 
gene locus. B) VCaP cells were processed, RNA collected and converted to cDNA as 
described in Fig. 3.8B. Gene expressions were quantified by qPCR using specific 
primers. GAPDH was used as an internal normalization control. Error bars represent 




3.13 VCL, a Tumor Suppressor in Prostate Cancer 
  
Within our defined gene set (Fig. 3.16A), we sought to identify novel AR target genes 
that are suppressed and facilitate metastasis in prostate cancer. From literature review, 
Vinculin (VCL) was identified as a potential candidate. VCL is a membrane cytoskeletal 
protein required for regulating focal adhesion turnover. This is a process important for 
proper cell movement (Saunders et al., 2006). Importantly, a previous study identified an 
interaction between VCL and the MET mediator, E-Cadherin. This interaction was found 
to be critical for mechanosensing enhancement (le Duc et al., 2010). We then turned to 
clinical data deposited in the Oncomine data for evidence that supported a role of VCL as 
a suppressor of cancer progression. In line with our expectations, we found the mRNA 
expression of VCL was low in primary prostate cancers and even lower in advanced 
metastatic counterparts. This was a trend that was supported by several clinical studies 
(Fig. 3.18A). Furthermore, we observed a negative correlation relationship between the 
mRNA levels of ERG and VCL (Fig 3.18B). Survival analysis using data from the Taylor 
et al clinical study (Taylor et al., 2010) also showed that patients with low expression of 
VCL have a significantly lower recurrence free survival (Fig. 3.18C), indicative of 
VCL’s postulated role as a tumor suppressor. Taken together, these clinical data were in 
concordance with our postulation of VCL as a potential novel AR target gene that is 

















Figure 3.18 Expression Levels of Vinculin in Clinical Prostate Cancer Studies 
A) Boxplots showing relative mRNA expression of VCL in clinical prostate samples 
from the MSKCC study and studies deposited in the Oncomine database. B) Scatterplots 
showing the correlation between the relative mRNA expression of VCL and the 
corresponding ERG mRNA expression in clinical prostate samples from the same studies 
in Fig. 3.18A. C) Kaplan-Meier survival curve showing the risk of biochemical relapse in 
prostate cancer patients expressing high (red line) or low (green line) VCL levels. Data 












3.14 VCL, an Androgen Induced Gene that is Suppressed by ERG, 
HDACs and EZH2 in VCaP Cells  
 
To provide evidence that inhibition of VCL directly links ERG and AR with prostate 
cancer progression, we first showed that VCL is a direct target of AR and ERG. As 
shown in our Chip-Seq data (Fig. 3.19A), AR and ERG are recruited to an intronic region 
of VCL. Interestingly, HDACs and EZH2 were also recruited to the same site (Fig. 
3.19B).  Furthermore, while androgens stimulate the expression of VCL, silencing of 
ERG via siRNA and the inhibition of HDACs/EZH2 by small molecules all led to 




































                                        
 
Figure 3.19 Suppression of Androgen Induced Upregulation of VCL by ERG, 
HDACs and EZH2 
A) Snapshot showing the co-localization of AR, ERG, HDACs 1-3 and EZH2 at a 
potential cis-regulatory element of VCL. B) The consequences of AR and ERG siRNA-
mediated depleteion on VCL expression in VCaP cells were assessed using methods as 
described in Fig. 3.8B. C) The consequences of TSA-mediated inhibition of HDACs on 
VCL expression in VCaP cells were assessed as described in Fig. 3.14B (bottom). D) The 
consequences of DZNep-mediated inhibition of EZH2 on VCL expression in VCaP cells 




3.15 Silencing of VCL Led to Increased Prostate Cancer Cell 
invasiveness 
 
Thus far, we have only provided correlative evidence that would support VCL role as a 
tumor suppressor in prostate cancer. It would be important to demonstrate the functional 
phenotypic effect of VCL suppression on prostate cancer progression. To address this 
question, we investigated the effect of VCL depletion on prostate cancer metastasis 
through performing invasion assays using VCaP cells with or without VCL depletion. In 
concordance with our postulated tumor suppressor role for VCL, our results showed that 
silencing of VCL (Fig 3.20A) culminated in an increase in the matrigel invasiveness of 
VCaP cells (Fig. 3.20B). Through performing PI FACs and BrdU assays, we confirmed 
that the increase in matrigel invasion capability of VCaP cells post VCL depletion was 
not due to decreased  cell death (Fig. 3.20C) or increased cell proliferation (Fig. 3.20D). 
To provide further support for the generality of VCL as a suppressor of cell invasion in 
prostate cancers, we also assessed the effect of VCL depletion on cell invasion in another 
prostate cancer cell line, LNCaP (Fig. 3.20E). Similar to VCaP cells, we also observed an 
increase in matrigel invasiveness of LNCaP cells after VCL depletion (Fig 3.20F). 
Overall, our results support the postulation that ERG, HDACs and EZH2 facilitate 
prostate cancer cell invasion and metastasis, in part, by suppressing AR-mediated 













































                          
Figure 3.20 VCL as a Suppressor of Invasion in Prostate Cancer Cells 
A) Western blot analysis of VCL expression in VCaP cells grown under normal full 
serum conditions and treated with control siRNA or siRNA against VCL. GAPDH was 
utilized as the loading control. B) VCaP cells, treated with control siRNA or VCL 
targeting siRNA, were used for Matrigel invasion assay. Bar charts showing the average 
number of cells that have passed through the transwell per high power field (HPF) (Top). 
Error bars represent S.E.M of at least 3 biological replicates. Representative high HPF 
images of siRNA treated VCaP cells that have passed through the transwell in a matrigel 
invasion assay (Bottom). C) Bar chart showing the percentage of VCaP cells in Sub G1 
phase after treatment with control siRNA or siRNA against VCL as assessed by PI FACs 
analysis. D) Bar chart showing the percentage of VCaP cells in S phase after treatment 
with control siRNA or siRNA against VCL as assessed by BrdU assay analysis. E) 
Western blot analysis of VCL expression in LNCaP cells grown under normal full serum 
conditions and treated with control siRNA or siRNA against VCL using GAPDH as the 
loading control. F) LNCaP cells, treated with control siRNA or VCL targeting siRNA, 
were used for Matrigel invasion assay. Bar charts showing the average number of cells 
that have passed through the transwell per high power field (HPF) (Top). Error bars 
represent S.E.M of at least 3 biological replicates. Representative high HPF images of 







Chapter 4: Discussion 
 
Previous research has established a close and intricate link between the output of AR 
transcriptional network and prostate cancer development (Debes and Tindall, 2002; 
Heinlein and Chang, 2004). Consequently, manipulation of the AR transcriptional 
activity as a therapeutic strategy against prostate cancer harbors the potential to be highly 
effective (Huggins, 1967; Huggins and Hodges, 2002). To facilitate the development of 
this form of therapeutics, a clear understanding of the transcriptional mechanisms 
underlying the AR transcriptional network is highly desired. 
  
AR-mediated transcription is a complex process encompassing a series of highly 
coordinated steps. The recruitment of the receptor, collaborative factors, coactivators, and 
corepressors had to occur in a temporal and spatial manner to ensure optimal 
transcriptional output. Furthermore, the transcriptional activity of AR at the different 
gene loci had to be independently regulated so as to achieve a precise transcriptional 
output driving the desired cellular phenotype.. From our understanding of the field, we 
noted that most of the studies to date have focused on the function of transcriptional 
coactivators such as SRCs and p300 in the activation of AR-mediated transcription. 
Although these studies have provided much knowledge into the workings of the AR-
mediated transcription, it is unfortunate that this does not provide a comprehensive view 
of the whole AR transcriptional network as the net transcriptional output is determined by 
a coordinated crosstalk between AR with both co-activators and co-repressors. 
Consequently, co-repressors are likely to also play a major role in the regulation of 
transcriptional output of the AR transcriptional network. For instance, the widely 
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overexpressed TMPRSS2-ERG was surprisingly shown to function as a repressor of AR-
mediated transcription (Sun et al., 2008; Yu et al., 2010b). Other than ERG, multiple 
transcriptional co-repressors (HDACs and EZH2) were also known to be overexpressed 
in prostate cancers (Varambally et al., 2002; Weichert et al., 2008). However, our 
understanding on the extent of androgen signaling attenuation by transcriptional co-
repressors at the genomic level and the resulting functional consequences on prostate 
cancer progression remains limited.  
 
We attempted to address this question with a genomic approach. Utilizing ChIP-Seq, we 
mapped out the genome-wide binding profiles of AR. ERG, HDAC1, HDAC2, HDAC3 
and EZH2 in prostate cancer cells prior and post androgen stimulation.  Briefly, we 
uncover an AR-centric transcriptional network consisting of the transcriptional repressors 
ERG, HDACs and EZH2. Our data suggest that the integration of transcriptional co-
repressors in AR transcriptional network provide the mechanism for regulated 
suppression of androgen signaling.  
 
Similar to a recent study (Yu et al., 2010b), which was published during the course of our 
work, we found widespread co-localization of AR and ERG after 2 hrs of DHT 
stimulation. This is indicative of a genome-wide transcriptional collaboration between the 
two factors in prostate cancer. Even though both our study and that of Yu et al. (Yu et al., 
2010b) showed substantial overlap between the cistromes of AR and ERG, our study 
provided several novel insights on the AR and ERG cross-talk. In contrast to the Yu et al. 
study (Yu et al., 2010b) which examine AR cistrome only after a prolonged duration of 
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androgen treatment and ERG cistrome under full serum condition, we have provided a 
comprehensive profile of AR and ERG cistrome in prostate cancer cells at both short and 
long time intervals after androgen stimulation and even under conditions of androgen 
deprivation. In addition, we treated the prostate cancer cells with a saturating 
concentration of DHT (100nM) as opposed to the other study (10nM). Consequently, we 
are likely to discover novel functional AR binding sites that are only occupied under 
androgen-saturated conditions as was shown by a recent study (Cai et al., 2011). 
Interestingly, our data showed that a substantial number of ERG unique and AR+ERG 
co-localized binding sites had prebound ERG prior to androgen treatment, suggestive of a 
pioneering role for ERG. This was an unexpected finding as the expression of ERG was 
shown to arise from a fusion event, resulting in it being induced upon androgen 
stimulation (Tomlins et al., 2005). Unlike the conventional pioneering factors, our time-
course ChIP-Seq data showed that the recruitment of ERG to AR+ERG co-localized 
binding sites can be further enhanced with short-term DHT stimulation even though some 
ERG is prebound prior stimulation. In contrast, the increment of ERG at ERG unique 
sites is mostly only observed after an increase in ERG protein levels on prolonged 
androgen stimulation. Apart from providing evidence for AR’s role as a facilitator of 
ERG recruitment to ARBS, this result also demonstrate ERG as an unique nuclear 
receptor transcriptional repressor different from other counterparts such as NKX3-1 and 
LEF-1, which exert their repressive function via competition with the Estrogen Receptor 
(ER) for binding to the ERBS (Holmes et al., 2008). Intriguingly, we also noticed that the 
promoters of androgen regulated genes were also frequently occupied by ERG in addition 
to the AR-bound enhancers. However, unlike ERG binding at AR-bound enhancers, their 
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occupancy at the promoters of androgen regulated genes was usually unresponsive to 
androgen stimulation. Further studies are required to address the functional relevance of 
ERG binding at the promoter region of androgen regulated genes in the attenuation of 
androgen signaling. 
 
The expression levels of HDACs and EZH2 were shown by recent studies to be 
positively correlated to that of ERG in prostate cancers (Gupta et al., 2010; Iljin et al., 
2006; Yu et al., 2010b). Interestingly, HDACs1-3 and EZH2 are also transcriptional 
repressors that were observed to be ovexpressed in prostate cancers (Varambally et al., 
2002; Weichert et al., 2008) and associated with prostate oncogenesis (Min et al., 2010; 
Wang et al., 2009a; Yu et al., 2010a; Yu et al., 2007b).  It is thus tempting to speculate a 
transcriptional collaboration between ERG, HDACs and EZH2 in the partial attenuation 
of AR transcriptional activity. Indeed, analysis of our generated ChIP-Seq data elucidated 
a complex and intricate transcriptional network between AR, ERG with other widely 
over-expressed transcriptional corepressor proteins (HDAC1, HDAC2, HDAC3, and 
EZH2) in prostate cancer cells. Interestingly, our study revealed a general increased in 
the occupancy of AR, ERG, HDAC2, HDAC3, and EZH2 to shared elements of the 
transcriptional network during androgen signaling, suggestive of a tightly regulated 
mechanism that is incorporated in the AR transcriptional program for feedback during 
androgen signaling. Whereas previous studies have demonstrated the recruitment of 
HDACs to ARBS, this was under the context of antiandrogen (casodex) stimulation 
(Shang et al., 2002) and not under androgen signaling. Even more unexpected was our 
finding on androgen-induced EZH2 recruitment to a substantial of ARBS enhancer sites, 
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an observation that suggests a role for EZH2 in transcriptional regulation, unique from its 
commonly perceived role as the catalytic enzyme for histone methylation at the 
promoters of repressed genes (Ku et al., 2008; Margueron et al., 2008; Yu et al., 2007a).  
 
Even though our study revealed some insights on the integrated transcriptional co-
repressor network of AR, ERG, HDACs and EZH2, our understanding of this network is 
still incomplete. For instance, the exact mechanism of co-operative action by ERG, 
HDACs and EZH2 in AR transcriptional attenuation remains largely unknown. 
Furthermore, we showed the involvement of HDACs and EZH2 in ERG-mediated 
suppression of androgen signaling in ERG-positive VCaP prostate cancer cells, their 
specificity to the type of regulatory elements remains unresolved. While we have shown a 
mild attenuation effect on AR transcriptional activity by HDACs and EZH2 in ERG-
fusion negative LNCaP cells, we acknowledge the need for a more comprehensive study 
to establish the role of HDACs and EZH2 in AR-mediated transcription in ERG-null 
prostate cancers.  
 
Although our work and others (Sun et al., 2008; Yu et al., 2010b) highlighted the role of 
ERG in attenuating AR  induced differentiation markers including PSA and FKBP5, 
there were  no major known direct functional roles for these genes in prostate cancer 
progression (Chen and Sawyers, 2010). An attenuated level of androgen signaling was 
suggested to be a common feature of metastatic and advanced prostate cancers (Yu et al., 
2010b). Importantly, studies have shown that a low AR content is responsible for 
epithelial mesenchymal transition (EMT) and invasion in prostate cancer cells (Zhu and 
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Kyprianou, 2010). Strikingly, ERG is also implicated to disrupt the cortical cytoskeletal 
network (Schulz et al., 2010), promote EMT and invasion in prostate cancers by 
upregulating matrix metalloproteinases (MMPs) (Tomlins et al., 2008), ZEB1/2 (Leshem 
et al., 2011) and through FZD4 (Gupta et al., 2010). So the question begets: Could ERG 
mediated suppression of AR signaling be a possible avenue for EMT in prostate cancers?  
In the EMT process, epithelial cytoskeletal and cell adhesion proteins including keratins 
and E-Cadherins are substituted with their mesenchymal counterparts such as Vimentin 
and N-Cadherins (Lee et al., 2006a). Composition alteration of the cell adhesion and 
cytoskeleton molecules will culminate into weaker cell adhesion and cell-cell cohesion. 
Consequently, this leads to enhanced cancer cell motility and invasiveness (Lee et al., 
2006a). Indeed, we observed that ERG could directly repress AR-mediated upregulation 
of epithelial cytoskeletal protein markers KRT8 and KRT18. Apart from epithelial 
cytokeratins, the androgen induced expression of the cytoskeletal protein Vinculin 
(VCL), was also repressed directly by ERG, together with HDACs1-3 and EZH2. VCL is 
a cytoskeletal protein responsible for regulating focal adhesion turnover (Saunders et al., 
2006) and hence cell motility. VCL was recently implicated to potentiate the 
mechanosensing function of E-cadherin (le Duc et al., 2010), an important adhesion 
molecule that suppressed metastasis in prostate cancers (Cao et al., 2008). In addition, 
VCL was also shown to stabilize E-cadherin expression at cell surface (Peng et al., 2010). 
These results highlight the importance of VCL to the optimal functionality of E-cadherin 
in regulating cell adhesion and cell motility. Interestingly, we showed that depletion of 
VCL also led to an increase in the invasive capability of prostate cancer cells. This 
suggests VCL role as an important androgen induced target that is repressed by ERG, 
123 
 
HDACs and EZH2 for prostate cancer progression. Analysis on clinical data also 
revealed an association between low VCL levels and advanced metastatic prostate 
cancers. On top of that, low VCL level was shown to be a predictor of poor prognosis in 
prostate cancer patients. Intriguingly, however, there was also recent data that showed 
non-conformity to the role of VCL as a general tumor suppressor in prostate cancers. For 
instance, enhanced proliferative capability was attributed to the amplification of the VCL 
gene in a subset of prostate cancers (Ruiz et al., 2011), as exemplified by the AR negative 
PC3 prostate cancer cell line model. On the hand, proliferation rate of the androgen 
sensitive 22Rv1 (Ruiz et al., 2011) and VCaP (in this study) prostate cancer cell line was 
unaffected by VCL depletion. Consequently, these results suggest a possible dual role of 
VCL in prostate cancer progression that is likely to sensitive to the levels of VCL under a 
specific cellular context. Again, further studies would be necessary to establish this 
postulation. 
 
At first sight, the notion deriving from our data that regulated partial suppression of 
androgen signaling drives prostate cancer progression seem to be contradictory to the 
generally accepted consensus that increased AR activity is associated with both naïve and 
castrate-resistant prostate cancer development. Certainly, the importance of high AR 
activity in prostate cancer progression is undisputable. The role of high AR activity in 
promoting prostate cancer cell survival and proliferation is well established (Liao et al., 
2005; Schiewer et al., 2012). An active and functioning AR was also widely recognized 
as driver for continued prostate cancer progression, crucial for the development, growth 
and survival of androgen independent prostate cancers (Chen et al., 2004; Wang et al., 
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2009b). For instance, with AR amplification, prostate cancer cells could become highly 
sensitive to basal levels of androgens, ensuring adequate AR transcriptional activation for 
continued prostate cancer cell proliferation and survival in patients that undergo androgen 
deprivation therapy (Chen et al., 2004). We are in full agreement with these accepted 
insights that AR activity is essential for prostate cancer progression. This is highlighted in 
our recently published paper that showed high AR activity being crucial for hormone 
naïve prostate cancer cell survival (Tan et al., 2012). However, we feel that our current 
data in this paper is not in opposition to these commonly accepted consensuses but offers 
an additional dimension to prostate cancer progression. We conclude that while an 
enhanced level of AR transcriptional output may drive cancer cell survival and 
proliferation, aberrant hyperactivation of the whole AR transcriptional program might be 
detrimental for prostate cancer progression to metastatic forms. This might be the 
explanation for studies that have observed a slowing of prostate cancer progression 
occurring under high doses of DHT treatment (Hofman et al., 2001; Tsihlias et al., 2000). 
In support, defined sets of androgen upregulated genes in our study and that of Yu et al. 
(Yu et al., 2010b) were both shown to be associated with overexpressed genes in prostate 
primary tumours (in comparison to normal prostate) and underexpressed genes in 
advanced and metastatic prostate cancers (in comparison to primary prostate tumors). 
This implies some forms of reduced androgen signaling in advanced and aggressive 
prostate tumours when compared to primary prostate tumours. Hyperactivation of AR 
might drive transcription programs associated with epithelial differentiation and thus 
inhibit metastasis. Indeed, a low level of AR content was shown to be necessary for an 
EMT phenotype in prostate cancers (Zhu and Kyprianou, 2010). Consequently, 
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regulation of androgen signaling in prostate cancer would be crucial for ensuring an 
equilibrium that allows for cancer cell proliferation, survival, as well as metastasis. To 
achieve this equilibrium level of androgen signaling, we speculate that multiple feedback 
mechanisms are likely to be incorporated in the AR transcriptional network. In fact, AR 
was recently shown to mediate its own transcriptional repression under high levels of 
androgens in prostate cancer cells (Cai et al., 2011). We speculate that this might be one 
of the possible feedback mechanisms for modulating androgen signaling repression. 
Additionally, we think that the integration of ERG and transcriptional co-repressors into 
the AR transcription network, discovered in this study, constitutes another level of 
feedback mechanism for maintaining an optimal androgen signaling output. Taken 
together, the results from this study are consistent with a dual opposing role of AR in 
driving proliferation and survival but inhibiting metastasis in prostate cancer and so to 
modulate the AR transcriptional output ideal for metastasis, a highly integrated 
transcriptional network of AR with ERG, HDACs and EZH2, functions to limit AR-
driven epithelial differentiation and to facilitate EMT via regulated suppression of AR 




















Chapter 5: Future Directions 
 
Thus far, our work had shed several interesting and novel insights on the AR-centric 
transcriptional network regulating prostate cancer progression, especially in relation to 
the fusion gene transcription factor, ERG, and the oncogenic transcription co-repressors, 
HDACs1-3 and EZH2. However, these findings are still vastly inadequate for a   
thorough understanding of AR, ERG, HDACs1-3 and EZH2 cross-talk. Future efforts 
should be directed to several areas. 
 
5.1 Determining the Transcriptional Mechanisms and the Specificity 
Underlying the AR-ERG-HDACs-EZH2 transcriptional Cross-Talk 
 
Notwithstanding the fact that our data have provided some evidence for the involvement 
of ERG, HDACs and EZH2 for regulated suppression of androgen signaling, the 
mechanistic details and the specificity of their actions is still very much unclear.  
Although HDACs/EZH2 binding to ARBS was established in our study to be somewhat 
androgen responsive, understanding of the factors regulating their recruitment remained 
incomplete. For instance, it is not known whether HDACs/EZH2 is recruited to the 
chromatin in response to AR and/or ERG chromatin occupancy. AR/ERG Knock-down 
HDACs/EZH2 ChIP experiments could be performed to better address this query. 
However, it will be a technically challenging feat if AR/ERG silencing leads to changes 
in the expression of HDACs/EZH2. Even though our current data have established a 
chromatin co-localization and a direct endogenous interaction between HDACs/EZH2 
with AR and ERG, the functionality of these factors as possible multi-protein complexes 
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ought to be resolved with further evidence from protein complex purifications and re-
ChIP experiments.  
To exploit this crosstalk as a possible therapeutic target, the transcriptional mechanisms 
undertaken by these co-factors in attenuating AR-mediated transcription ought to be 
thoroughly addressed. For example, it would be important to determine the exact location 
of the endogenous interactions between the transcription factors and the essentiality of 
the interactions on ERG/HDACs/EZH2 suppression of AR-mediated transcription. It 
would also be interesting to assess if the influence of HDACs/EZH2 recruitment on the 
acetylation and/or methylation status of histones and/or other transcriptional 
collaborators. This is especially so for EZH2 as a recent study had proposed a SET-
independent function of EZH2 in regulating transcription (Lee et al., 2011) .    
 
5.2 Unraveling the 3 Dimensional Transcriptional Interactome of the 
AR-ERG Cross-Talk 
 
The genome is not a 2-dimensional system. Data in this study have revealed a complex 
network of multiple promoters and enhancers. The enhancers are found to be interspersed 
throughout the genome with no obvious patterns relative to the regulated genes. To 
function, the enhancers had to communicate with each other and with specific promoters 
though the spatial nuclear space via chromatin looping. Consequently, analysis of the 3 
dimensional transcriptional interactome would be essential for comprehending the AR-
ERG crosstalk. This kind of information would be helpful to the validation and 
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characterization of the potential communication between AR enhancers with ERG-
bound/unbound promoters.  
Recently, AR-mediated chromosomal looping was attributed as a facilitator for the 
formation of certain chromosomal rearrangements in prostate cancers. Specifically, 
studies have shown that TMPRSS2-ERG gene fusions could be made to form de-novo in 
TMPRSS2-ERG fusion negative LNCaP cells that were stimulated by androgens and 
exposed to genotoxic stress, facilitated by AR-mediated chromatin interactions between 
regions of the TMPRSS2 loci and the ERG loci (Lin et al., 2009; Mani et al., 2009). Of 
high interest, research on clinical prostate cancer samples has suggested chromosomal 
rearrangements to be associated with ETS-fusion positive status (Pflueger et al., 2011)  
and AR and ERG binding sites to be enriched with chromosomal DNA breakpoints 
(Berger et al., 2011). These findings imply the involvement AR and ERG in mediating 
chromosomal rearrangements through chromosomal looping. 
Analysis of the 3 dimensional transcriptional interactome would be crucial to  
understanding the role of AR and ERG in mediating chromosomal interactions. Newly 
developed genomic technology such as ChIA-PET (Fullwood et al., 2009) and Hi-C 
(Lieberman-Aiden et al., 2009) would be most apt for these studies. However, to date, no 
such studies have been carried out in prostate cancer cells. To address this gap of 
knowledge, we have actually generated an AR ChIA-PET library in VCaP cells and in 
the process of doing so for an ERG ChIA-PET. We believe that the analysis of these 
maps will provide unprecedented information that could help resolve the role of AR and 
ERG in mediating chromosomal interactions. 
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5.3 Delving Deeper into the Downstream Functional Consequences of 
the AR-ERG-HDACs-EZH2 Transcriptional Crosstalk 
 
In this study, we have tried to address the potential therapeutic implications of the AR-
ERG-HDACs-EZH2 transcriptional crosstalk through investigating the downstream 
functional consequences of this transcriptional network. From this, we could also 
establish potential therapeutic targets and/or biomarkers targeting this cross-talk. In that 
regard, we have identified VCL as a novel AR-induced downstream functional target that 
is suppressed by ERG, HDACs and EZH2 to facilitate prostate cancer metastasis. This is 
a substantial advancement compared to past studies which only identified differentiation 
markers with no known functional influence in prostate cancer progression  (Chen and 
Sawyers, 2010).  However, this is still insufficient. Our analysis had revealed the AR-
ERG-HDACs-EZH2 crosstalk as an extensive genome-wide transcription network. 
Consequently, it would be almost a certainty that VCL is not the only gene regulated by 
this crosstalk. Future efforts should be aimed at elucidating the whole regulated 
transcriptome and identifying other regulated genes that exhibit functional relevance in 
driving prostate cancer progression.   
 
5.4 Bringing Clinical Relevance onto the AR-ERG-HDACs-EZH2 
Transcriptional Cross-Talk 
 
Since our main goal is to formulate clinical therapies for prostate cancer, it is an 
eventuality that we need to validate our findings under clinical settings.  ChIP-Seq assays 
of AR, ERG, HDACs and EZH2 should also be carried out in a panel of patients’ prostate 
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tumor samples to validate the existence of the transcriptional network clinically. 
Although this has already been done in prostate tumors for AR and ERG (Yu et al., 
2010b), we believe that it will be a technical challenge with transcriptional co-repressors 
such as HDACs and EZH2 which usually does not bind to DNA directly. Transcriptome 
profiling of the prostate tumor samples should also be carried out as complementation to 
the elucidated cistromic profiles. These data should be integrated and correlated to the 
clinical parameters such as cancer stage, subtype and prognosis to derive possible clinical 
significance. Immunostaining for the presence of the downstream targets (i.e. VCL) of 
the crosstalk and evaluating their correlation with clinical parameters (i.e. cancer 
subtype) of the prostate tumors would establish much support and validity for the clinical 












Chapter 6: Conclusion Remarks 
 
A comprehensive understanding of the AR transcriptional network in prostate cancers 
would provide valuable information on prostate cancer initiation, development and 
maintenance, critical to the advancement of prostate cancer diagnostics and therapeutics. 
In addition, research into the AR transcriptional network could yield insights on nuclear 
receptor biology and possibly provide the basis for understanding hormone response and 
transcriptional regulatory mechanisms in general. Research so far has allowed us to 
progress from the primitive understanding of AR as a transcription factor that recruits 
polII to up-regulate transcription. Currently, we are beginning to understand that the AR 
transcriptional network is not a rigid, two-dimensional system that could produce only an 
all-or-none output. Rather, the AR transcriptional circuitry is a system that exhibits high 
plasticity and complexity, both spatially and temporally, with the degree of the output 
determined through specific interactions with a diversity of transcriptional co-factors, 
both co-activators and co-repressors. With the inherent plasticity, only then the AR 
network is able to evolve and adapt under different cellular environments and context to 
meet the needs of prostate cancer progression. To be able to formulate strategies to target 
effectively this “plasticity” therapeutically, it would be important for us to comprehend 
the intricate complexities of the transcriptional cross-talks between AR and other 
important transcription collaborators. For instance, such knowledge would also be useful 
in establishing predictive models for the AR transcriptional output during therapy. In this 
work, we have provided some preliminary insights into the cross-talk of several 
transcription factors that are commonly overexpressed in prostate cancers, namely, ERG, 
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HDACs1-3 and EZH2, with AR. Although our findings here is not fully comprehensive, 
we believed that our study herein has provided a strong basis and a good resource for 
future work that aim to further delineate the regulatory role of ERG, HDACs1-3 and 


















List of Fosmid Probes 
(Mani et al., 2009) 
For Detecting Gene Rearrangement within the ERG locus  
1
st
 Probe for ERG loci: RP11-476D17 
2
nd
 Probe for ERG loci: RP11-95I21 
 
For Detecting Fusion between TMPRSS2 and ERG 
Probe for ERG loci: RP11-476D17 





















List of qPCR Primers 
ChIP-qPCR Primers  Sequence  
PLA1A_ChIP_F  AGTGGGAGAGGTGCAGGAAA  
PLA1A_ChIP_R  TGAAACACACTGTCCCTCTTTGA  
FKBP5_ChIP_F  CTTCACGCCTGTGTGCTTTTAT  
FKBP5_ChIP_R  AGGGTGCAGGACGTTCCA  
PSA_ChIP_F  TGGGACAACTTGCAAACCTG  
PSA_ChIP_R  CCAGAGTAGGTCTGTTTTCAA  
c36_ChIP_F  AACAGGCATTATTGTCTTTGAAAAAG  
c36_ChIP_R TCTCATTCTGTGGCTGTGTACTCTCT  
CTRL1_ChIP_F (AR/ERG ChIP)  CCTGGAGGGCTTGGAGAT 
CTRL1_ChIP_R (AR/ERG ChIP)  ATCCTACGGCTGGCTGTGA 
CTRL2_ChIP_F (HDACs/EZH2 ChIP)  GTTTTCCATCTTTTCCAGTTGTCTATAA  











































ERG_Forward  CGCAGAGTTATCGTGCCAGCAGAT  
ERG_Reverse  CCATATTCTTTCACCGCCCACTCC  
AR_Forward  GTGTCACTATGGAGCTCTCACATGT  
AR_Reverse  GTTTCCCTTCAGCGGCTCTT  
PSA_Forward  TGTGTGCTGGACGCTGGA  
PSA_Reverse  CACTGCCCCATGACGTGAT  
FKBP5_Forward  GGCTGGCAGTCTCCCTAAAA  
FKBP5_Reverse  ATCAAGGAGCTCAATCTCAAAAAAG  
KRT8_Forward CAGGCAGCTATATGAAGAGGAGATC  
KRT8_Reverse  ATGGACAGCACCACAGATGTG  
KRT18_Forward  GCGAGGACTTTAATCTTGGTGATG  
KRT18_Reverse  TGGTCTTTTGGATGGTTTGCA  
VCL_Forward  CCTCGTCCGGGTTGGAA  
VCL_Reverse  TAAATGCTGGTGGCATATCTCTCT  
GAPDH_Forward  GGCCTCCAAGGAGTAAGACC  
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